Tumor angiogenesis: causes, consequences, challenges and opportunities

  • Roberta Lugano
  • Mohanraj Ramachandran
  • Anna DimbergEmail author
Open Access


Tumor vascularization occurs through several distinct biological processes, which not only vary between tumor type and anatomic location, but also occur simultaneously within the same cancer tissue. These processes are orchestrated by a range of secreted factors and signaling pathways and can involve participation of non-endothelial cells, such as progenitors or cancer stem cells. Anti-angiogenic therapies using either antibodies or tyrosine kinase inhibitors have been approved to treat several types of cancer. However, the benefit of treatment has so far been modest, some patients not responding at all and others acquiring resistance. It is becoming increasingly clear that blocking tumors from accessing the circulation is not an easy task to accomplish. Tumor vessel functionality and gene expression often differ vastly when comparing different cancer subtypes, and vessel phenotype can be markedly heterogeneous within a single tumor. Here, we summarize the current understanding of cellular and molecular mechanisms involved in tumor angiogenesis and discuss challenges and opportunities associated with vascular targeting.


Angiogenesis Cancer Endothelial Vascular targeting VEGF Anti-angiogenic therapy 


Malignant cells require oxygen and nutrients to survive and proliferate, and therefore need to reside in close proximity to blood vessels to access the blood circulation system. The early observation that rapidly growing tumors were heavily vascularized, while dormant ones were not, led Judah Folkman to propose that initiation of tumor angiogenesis was required for tumor progression [1]. Further, Folkman isolated a tumor-derived factor that induced angiogenesis [2] and hypothesized that inhibition of angiogenic signaling pathways might block new vessel formation and result in tumor dormancy. This exciting concept attracted considerable interest from the research community and spurred extensive efforts dedicated to isolating tumor-derived pro-angiogenic factors and delineating their signaling pathways [3]. In 2003, a clinical trial demonstrating prolonged survival of patients with metastatic colorectal cancer when chemotherapy was administrated in combination with humanized neutralizing antibodies targeting anti-vascular endothelial growth factor (VEGF) resulted in an FDA approval and provided proof-of-concept that anti-angiogenic therapy can be successfully used to treat cancer [4]. Subsequently, several antibodies and tyrosine kinase inhibitors designed to target pro-angiogenic signaling have been approved as cancer therapies. Despite the ever-growing list of FDA-approved drugs, the success of anti-angiogenic therapy has so far been quite limited, only providing short-term relief from tumor growth before resistance occurs and typically resulting in modest survival benefits. The limited efficacy has several explanations including tumors employing alternative modes of angiogenesis and development of resistance mechanisms. In addition, many tumors can obtain access to blood supply through vascular co-option, bypassing the need of tumor angiogenesis [5]. In this review, we summarize the current understanding of molecular and cellular mechanisms involved in tumor angiogenesis, the molecular and functional heterogeneities of tumor vessels and emerging concepts for vascular targeting during cancer therapy.

Initiation of tumor vascularization: the angiogenic switch

Small dormant tumors that are devoid of active blood vessel formation can frequently be observed in human tissue and in genetically engineered mouse models of multistage carcinoma at early stages of cancer progression. Tumor progression is often accompanied by ingrowth of blood vessels, consistent with a need for malignant cells to have access to the circulation system to thrive. Tumors can be vascularized either through co-option of the pre-existing vasculature [5], or by inducing new blood vessel formation through a variety of molecular and cellular mechanisms briefly described below. Vascular homeostasis is regulated by a large number of pro- and anti-angiogenic factors. When these are in balance, the vasculature is quiescent and endothelial cells are non-proliferative. Initiation of blood vessel formation is induced when pro-angiogenic signaling is dominating, a process that in tumors has been coined the “angiogenic switch” [6]. The angiogenic switch releases tumors from dormancy and sparks rapid growth of malignant cells in association with new blood vessel formation. The development of genetically engineered mice modelling multistage tumor progression has been instrumental in investigating the angiogenic switch. One of the most widely studied models is the RIP1-Tag2 model of pancreatic insulinoma expressing the semian virus 40 large T (SV40T) oncogene under the rat insulin promoter, which was developed in Douglas Hanahan’s laboratory [7]. In this model, tumors develop sequentially in mice carrying the transgene, initiating as non-angiogenic clusters of dysplastic cells, of which a proportion later develop to small angiogenic tumor islets that can progress to large vascularized tumors that metastasize to the lung. By combining this and other murine tumor models with advanced in vitro and in vivo models of angiogenesis [8], a wide range of factors and cellular mechanisms have been described that can initiate vessel formation in tumors. The angiogenic switch can be triggered either by additional genetic alterations of tumor cells, leading to increased proliferation and hypoxia or expression of pro-angiogenic factors, or by tumor-associated inflammation and recruitment of immune cells.

Mechanisms of blood vessel formation in tumors

The blood circulation system is critical in delivering nutrients and chemicals to tissues, removing waste products, and maintaining homeostasis. The vascular system, composed of the aorta, arteries, capillaries and veins transports blood throughout the body. Arteries carry blood away from the heart, transporting oxygenated blood to the tissues. The capillary networks have narrow walls that help in gas exchange between the blood and tissues. Oxygen is released into the tissues and carbon dioxide is absorbed by the blood, and is transported back to the heart through veins. Transmigration of immune cells into tissues is facilitated by post-capillary venules. The capillary wall is made of an endothelial cell layer surrounded by a basement membrane and is supported by pericytes. Angiogenesis is typically initiated from the capillaries and it plays an important part in tumor growth, maintenance and metastasis. Blood vessel formation in tumors can be induced through several cellular processes (Fig. 1) as briefly summarized below.
Fig. 1

Mechanisms of blood vessel formation. Neo-vascularization in normal tissues and tumors occur through one or more of the following mechanisms: a Sprouting angiogenesis: a process involving formation and outgrowth of sprouts (tip cells), which eventually fuse with an existing vessel or newly formed sprout. b Intussusceptive angiogenesis: the formation of new vasculature where a pre-existing vessel splits in two. c Vasculogenesis: prenatal neo-vascularization from endothelial progenitor cells. The endothelial progenitor cells proliferate and form lumens, eventually assembling into new blood vessels. d Recruitment of endothelial progenitor cells: vessel formation in tumors by recruitment of circulating endothelial progenitor cells. e Vascular mimicry: a matrix-embedded fluid-conducting meshwork formed by tumor cells. f Trans-differentiation of cancer stem cells (CSC): neo-vascularization in tumors through differentiation of CSCs to endothelial cells

Sprouting angiogenesis

New capillaries can bud from parental vessels through a multi-step process known as sprouting angiogenesis. Formation of sprouts involves (a) Tip cell selection: a cell from the parent vessel becomes the migratory leading cell and blocks its neighboring cells from adopting a tip cell fate by a lateral inhibition process. (b) Sprout extension: the tip cell migrates along the chemotactic path, followed by trailing stalk cells and (c) Lumen formation: connection of the luminal space of the sprout with the parent vessel. The developing sprout then connects with other vessels through a process called anastomosis.

Endothelial cells are normally quiescent, but can be induced to sprout and initiate angiogenesis by pro-angiogenic factors including vascular endothelial growth factor (VEGF). Tip and stalk cell selection is regulated through cross-talk between the VEGF and Dll4/Notch pathways [9]. In response to VEGF, tip cells produce Delta-like-4 (DLL4) ligand, platelet derived growth factor-B (PDGF-B), VEGF receptor-2 (VEGFR-2) and VEGFR-3/Flt-4 [10, 11, 12]. VEGF blocks Notch signaling and enhance sprouting, branching, migratory capacity and filopodia formation in tip cells [13]. DLL4 secreted by tip cells activated Notch signaling in the neighboring endothelial cells, suppressing tip cell formation by inhibiting VEGFR2 and VEGFR3 expression and inducing VEGFR1 (decoy for VEGF) expression [14, 15, 16, 17]. Tip cells extend numerous filopodia, and acquire motile and invasive phenotypes, secreting matrix degrading proteins that guide new blood vessel formation towards the VEGF gradient [18]. Neuropilins, which are non-tyrosine kinase receptors, promote tip cell function by enhancing signaling through VEGFR2 and VEGFR3 [19, 20]. Stalk cells follow the tip cells and branch out from the parent vessel, establishing the vascular lumen and junctional connections to the forming sprout. They are more proliferative and have fewer filopodia as compared to the tip cells, a process fine-tuned by Notch-regulated ankyrin repeat protein [21]. The term vascular anastomosis defines development of junction between two new sprouts (‘head-to-head’ anastomosis) or a sprout and an existing blood vessel (‘head-to-side’ anastomosis). Live imaging studies in Zebrafish indicate that development of cell junctions is a highly stereotypical process [22, 23, 24]. Migrating tip cell filopodia express junctional proteins such as VE-cadherin [25, 26]. The filopodia from adjacent tip cells make and break contacts many times during initial contact formation, after which VE-cadherin is deposited at a single point of filopodia contact and a ring shaped junction is formed to create a small luminal pocket at this site [22, 25, 27]. Next, the excess filopodia retract, membranes of the anastomosing fuse, express apical markers like podocalyxin, and upregulate expression of junctional molecules on the cell surface [25]. The different mechanisms by which the lumen and perfused tubes form are termed type I and type II anastomosis, reviewed in detail by Betz et al. [28].

Intussusceptive angiogenesis

A less studied process of neo-angiogenesis is “intussusception”, where transluminal tissue pillars develop within existing vessels and subsequently fuse to remodel the vascular plexus, first described in remodeling of lung capillaries [29, 30]. The molecular mechanisms involved in intussusceptive angiogenesis are not completely understood, but the process can be induced by growth factors including VEGF, PDGF and erythropoietin [31, 32, 33]. Intussusceptive angiogenesis have been observed in various tumor types including melanoma, colorectal cancer, glioma and mammary tumors [34, 35, 36, 37]. In melanoma, VEGF expression correlates with the occurrence of intussusceptive angiogenesis and the number of intraluminal tissue folds [34]. Xenografts of human adenocarcinoma utilize intussusceptive angiogenesis as a mode for rapid vascular remodeling and maintenance of blood flow in tumors [36]. Intususceptive angiogenesis is thought to contribute to tumor growth by increasing the complexity and number of microvascular structures within the tumor.

Vasculogenesis and recruitment of endothelial progenitor cells

De novo blood vessel formation in the embryo is induced through differentiation and association of endothelial progenitor cells (EPCs) in a process coined vasculogenesis [38, 39]. In mice, progenitor cells differentiate and assemble into clusters called blood islands, as early as embryonic day (E) 6.5–7 [40]. A subset of cells located at the perimeter of the blood islands, termed angioblasts give rise to precursors for endothelial cells, while those at the center differentiate to hematopoietic cells. Angioblasts migrate to the paraxial mesoderm, assemble into aggregates, proliferate and differentiate to form a plexus with endocardial tubes in mouse. This leads to formation of dorsal aortae, cardinal veins and the embryonic stems of arteries and veins in the yolk sac. Vasculogenesis is also described in adults during capillary formation post ischemia [41] or in tumors as alternative mechanism for neo-vascularization to meet the increasing need for oxygen and nutrient supply [42]. In preclinical glioma models, it has been shown that revascularization that occurs during glioma recurrence after irradiation is mediated by vasculogenesis and not angiogenesis [43]. Vasculogenesis in tumors is mediated by recruitment of EPCs or bone marrow–derived hematopoietic cells, resulting in the formation of new vessels to support tumor growth [44, 45]. EPCs are mostly unipotent adult stem cells that have the capacity to self-renew, proliferate, take part in neovascularization and repair endothelial tissue [46, 47]. They were first identified in 1997 by Asahara et al. [41]. EPCs are characterized by expression of CD34, VEGFR1, CD133, Tie-2 (endothelial receptor tyrosine kinase), Nanog and Oct-4 (Octamer-4), and by their ability to bind Ulex-lectin and uptake acetylated low-density lipoproteins [48, 49]. EPCs can be derived from hematopoietic stem cells, myeloid cells, circulating mature endothelial cells or other circulating progenitor cells [46, 50]. EPCs contribute to postnatal vasculogenesis, and are recruited from the bone marrow to sites of injury via growth factors, cytokines and hypoxia-related signaling pathways, where they differentiate into mature endothelial cells and incorporate themselves into sites of active neovascularization [41, 51]. In tumors, vasculogenesis is initiated by crosstalk between tumor cells and EPCs in the bone marrow. VEGF in the tumor microenvironment mobilizes VEGFR2+ EPCs from the bone marrow [52, 53, 54]. Tumors also secrete other factors well known to mobilize EPCs to the tumor bed and promote neovascularization, including chemokines C–C motif ligand (CCL)2 and CCL5, the hypoxia responsive chemokine CXCL12 (also known as SDF-1) [55] and adiponectin [55, 56, 57].

Vascular mimicry

Aggressively growing tumor cells can form vessel like structures through a process denoted as vascular mimicry. These structures, which are formed without contribution of endothelial cells, represents an alternate channel for tumor cells to source sufficient blood supply and nutrients. Vascular mimicry has been observed in many tumor types including melanoma [58], glioma [59], head and neck cancer [60], lung cancer [61], colorectal cancer [62] and prostate cancer [63]. The existence and relative importance of vascular mimicry was initially debated and questioned in the field [64], but has since been supported by findings of several research groups [65]. Structures formed through vascular mimicry are identified in tumor samples with IHC using CD31 and periodic acid–Schiff (PAS) as markers [66]. The endothelial-like tumor cells can secrete collagens IV and VI, proteoglycans, heparan sulfate, laminin and tissue transglutaminase antigen 2, aiding in tubular structure formation and stabilization [67]. Tumor cells participating in vascular mimicry in uveal melanoma have a multipotent, stem cell-like phenotype and express CD271 [68]. Both vascular mimicry and fibrovascular septa are present in the stroma of melanoma and can be distinguished by their thickness and lamination [69].

Vascular mimicry can contribute to tumor progression in several ways. In melanoma, mitochondrial reactive oxygen species induce activation of the Met proto-oncogene under hypoxic conditions, promoting vascular mimicry. This results in tumor cell motility, invasion, and metastasis [70]. In gliomas, increased vascular mimicry has been reported following anti angiogenic therapy [71]. This may serve as an alternative neovascularization process adopted by the tumor to cope with the therapy and counteract the hypoxic environment. Vascular mimicry is a marker for poor prognosis in several cancer types [62, 72]. However, there is a lack of techniques that can be used to clearly distinguish vascular mimicry from normal endothelial cell lining, which hampers investigations of the relative importance of this process.

Trans-differentiation of cancer stem cells

Trans-differentiation of cancer stem cells to endothelial cells and vascular smooth muscle-like cells, giving rise to neovascularization, has been reported in several tumor types [59, 73, 74, 75, 76]. Tumor endothelial cells have in some studies been observed to harbor similar somatic mutations as the malignant cells of the tumor, indicating a neoplastic origin [59, 73]. Trans-differentiation of glioma cells to endothelial cells in vitro was demonstrated by culturing of glioma cancer stem cells in endothelial-promoting media, resulting in expression of pan-endothelial markers CD31, CD34 and vWF, formation of tubular structures and uptake of LDL [59, 77]. In vivo xenografts of human glioma stem cells were observed to develop tumor vessels with endothelial cells expressing human endothelial proteins CD34, CD144, and VEGFR2. Selective therapeutic targeting of tumor-derived cells expressing Tie-2 could disrupt the vasculature and eradicate the tumor, leading the authors to conclude that glioma stem cell derived endothelial cells contributed to vascularization of glioma [59]. However, these results have been controversial and the clinical relevance has been questioned since endothelial cells in human glioblastoma have not been observed to harbor genetic alterations in other studies [78, 79]. Notably, Tie-2 is not only a marker of endothelial cells, but is also expressed by proangiogenic monocytes and pericytes [80]. A later study using lineage-specific fluorescent reporters did not support tumor cells as a source of endothelial cells in glioma, instead demonstrating that glioma cancer stem cells can differentiate into pericytes and that specific depletion of pericytes disrupted tumor vessels and tumor growth [81]. The trans-differentiation of glioma cancer stem cells to pericytes was enhanced by TGFβ, and their recruitment to endothelial cells was mediated by CXCL12/CXCR4 signaling [81].

Molecular and functional features of tumor blood vessels

While physiological blood vessels formation occurring during development, menstrual cycle or wound healing is a tightly controlled process that ceases when the need for new blood vessels have been met, tumor angiogenesis is deregulated due to a persistence of pro-angiogenic factors in the tumor microenvironment. Efficient circulation depends on an ordered division of the vascular tree into arteries, arterioles, capillaries, venules and veins. However, in the presence of constant pro-angiogenic signaling in the tumor, the newly formed vascular networks may fail to mature and prune, the division into arterioles, capillaries and venules may be lacking, vessel caliber size can be markedly heterogeneous and blood flow through the poorly organized and malformed vessels can be chaotic [82, 83]. This can lead to uneven blood flow within the tumor parenchyma resulting in areas of persisting or intermittent hypoxia [84, 85]. Endothelial junctions are often disrupted in tumor vessels, leading to enhanced permeability, and interstitial fluid pressure is increased [86]. This can in turn reduce the efficacy of cancer therapy since compression of tumor vessels and poor vascular perfusion hamper drug delivery [87]. Pericytes are generally partially detached from endothelial cells in tumor vessels, and the basement membrane is unevenly distributed, leading to increased vessel fragility and risks of hemorrhage [88, 89, 90]. Defects in vascular function and integrity profoundly alters the tumor microenvironment (Fig. 2a–c). However, the extent of structural and functional abnormalities observed in tumor vessels vary greatly depending on the tumor type and anatomical location, and also within the same tumor depending on the tumor microenvironment.
Fig. 2

Morphological and functional characteristics of tumor vessels as compared to normal vessels. a Normal vessels display an organized and hierarchical branching pattern of arteries, veins, and capillaries. In healthy vessels, endothelial cells are supported by basal membrane and pericytes coverage and they are tightly connected by stable cell-cell junctions. b Tumor vessels are morphologically and functionally different from normal vessels. In response to persistent and imbalanced expression of angiogenic factors and inhibitors, tumor vessels display an unorganized network lacking of a hierarchical vessel division. Tumor vessels are characterized by reduced blood flow, endothelial cell sprouting, disruption of endothelial cell junctions, loss of pericytes coverage and increased vessel leakiness resulting in increased tissue hypoxia and intravasation of tumor cells. Moreover, tumor endothelial cell basal membrane is abnormal, including loose associations with endothelial cells and variable thickness. c Tumor vessel abnormalization shown by immunofluorescent staining for the vessel marker CD31 (green) in an orthotopic syngeneic mouse model of glioma growing in the brain

Aside from the structural and functional defects observed within the tumor vasculature, tumor blood vessels are molecularly distinct from normal vessels since they respond to environmental cues by transcriptional regulation of gene expression [91, 92, 93, 94, 95, 96, 97, 98, 99]. Transcriptional signatures of tumor endothelial cells may vary depending on the anatomic location, the tumor type and the malignancy grade. However, tumor vessels typically up-regulate subsets of genes that are transcriptionally active also during developmental and physiological angiogenesis. Consistent with this, a meta-analysis of transcriptional profiles from different types of human cancer identified a core gene signature including, e.g. VEGFR2, TIE1 and TIE2 which are central regulators of pro-angiogenic VEGF and angiopoietin signaling [100]. This tumor angiogenesis core gene signature also included CLEC14A and CD93, which together with endosialin and thrombomodulin constitute a C-type lectin family that are frequently up-regulated in tumor vessels [95, 101, 102, 103, 104, 105, 106]. CLEC14A, CD93 and endosialin all bind to the secreted extracellular matrix associated protein multimerin-2 [107, 108]. The interaction between endothelial CD93 and MMRN2 regulates fibronectin deposition during glioma angiogenesis, and loss of endosialin, mainly expressed in pericytes, protects against development of fibrosis, suggesting that this protein family participates in regulating the extracellular matrix [105, 109]. However, CD93-deficiency is associated with increased permeability, while endosialin expression in pericytes promotes intravasation of tumor cells and metastatic dissemination, indicating opposite roles in regulating vascular integrity [104, 110]. The specific transcriptional response of tumor endothelial cells is not only related to angiogenesis and vessel integrity, but may also affect endothelial activation and recruitment of leukocytes. Pro-angiogenic signaling leads to endothelial anergy, reduced response to pro-inflammatory signaling and decreased regulation of adhesion molecules and chemokines necessary for capture and trans-endothelial migration of leukocytes [111, 112, 113, 114]. Up-regulation of FASL in tumor vessels further strengthens the endothelial barrier and contributes to immune suppression by inducing apoptosis of cytotoxic T-lymphocytes [115]. Similarly, expression of endothelin B in tumor vessels in ovarian cancer has been shown to decrease T cell homing [116]. Especially in brain tumors, the changes in endothelial gene expression induced by the tumor microenvironment can also be beneficial for therapy. The specific gene expression signature induced in tumor endothelial cells in WNT-medulloblastoma leads to disruption of the blood brain barrier and thereby renders the tumor sensitive to chemotherapy [117]. Proteins that are up-regulated in tumor vessels alter vascular function, and may constitute new targets for therapy as discussed further below.

Growth factor and chemokine signaling in tumor angiogenesis

A large number of pro-angiogenic factors and their cognate receptors are known to promote vessel formation in tumors, including vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF-2), platelet derived growth factor (PDGF), angiopoietins, ephrins, apelin (APLN) and chemokines. These factors are often expressed simultaneously, effectively co-operating at different stages of tumor angiogenesis. The main functions and features of the most prominent pro-angiogenic factors are discussed briefly below.

Vascular endothelial growth factors (VEGF)

The vascular endothelial growth factor family consists of five secreted proteins, VEGF (also referred to as VEGF-A), VEGF-B, VEGF-C, VEGF-D and placental growth factor (PlGF).

VEGF, originally identified as vascular permeability factor (VPF), is one of the most potent inducers of angiogenesis [118]. In cancer, VEGF is produced and secreted by tumor cells and surrounding stroma and is associated with tumor progression, increased vessel density, invasiveness, metastasis and tumor recurrence [119].

VEGF is up-regulated during hypoxia and orchestrate blood vessel formation mainly via activation of VEGF receptor-2 (VEGFR-2) expressed by endothelial cells [120]. VEGFR-2 activation initiates several signaling pathways leading to specific endothelial responses such as cell survival, proliferation, migration, invasion, vascular permeability and vascular inflammation [121]. A tight coordination of these cellular processes is crucial for a successful establishment of new vessels. During tumor angiogenesis, VEGF secreted by tumor cells induces endothelial cell proliferation and survival primarily via the ERK and PI3K/Akt pathways [122, 123]. Endothelial cell migration downstream of VEGFR2 is induced via multiple signaling pathways, often involving PI3K stimulation and activation of Rho GTPases [124]. On the other hand, VEGF-mediated cell invasion is promoted by the expression of MT (membrane type)-MMP (matrix metalloproteinase), MMP-2, MMP-9 and urokinase plasminogen activator which degrade the basal membrane and extracellular matrix allowing migration of endothelial cells and the formation of capillary sprouts [123, 125].

Vascular permeability is crucial for normal tissue homeostasis and is considered a prerequisite for VEGF-induced angiogenesis. VEGF induces vascular permeability by several mechanisms, including junctional remodeling, induction of fenestrae, and vesiculo-vascular organelles (VVOs) [126]. In pathological conditions such as cancer, dysregulation of these mechanisms leads to vascular hyper-permeability that in turn may exert direct effects on the tumor microenvironment including increased interstitial pressure and impaired therapeutic delivery [127]. Moreover, the leaky vasculature may facilitate the escape of tumor cells into the bloodstream promoting the establishment of distant metastases [128].

Vascular permeability is tightly related to vascular inflammation. Although VEGF is not an inflammatory cytokine, VEGF can induce the activation of the transcription factor NFAT in endothelial cells via PLCγ/calcineurin, promoting an inflammatory gene expression pattern similar to that of IL-1β [129]. In addition, VEGF-mediated activation of NF‐κB downstream of Akt can induce an inflammatory‐type response, promoting the attraction of leukocytes that can contribute to the angiogenic process. [123].

PlGF is a member of the VEGF family; however, its role in modulating tumor angiogenesis has been a subject of controversy. PlGF has been reported to enhance pathological angiogenesis by initiating a cross-talk between VEGFR-1 and VEGFR-2 [130], while others have demonstrated anti-angiogenic properties of PlGF [131]. Similarly, there have been contradictory results regarding the efficiency of anti-PlGF therapy in inhibiting angiogenesis and halting tumor growth in preclinical tumor models [132, 133].

Fibroblast growth factor-2 (FGF2)

The mammalian fibroblast growth factor (FGF) family comprises 22 molecules, 18 of which interact with high affinity to tyrosine kinase receptors FGFR1, FGFR2, FGFR3 and FGFR4 [134]. FGFs are secreted glycoproteins that are sequestered in the extracellular matrix. To signal, FGFs are released from the extracellular matrix by heparinases, proteases or specific FGF binding proteins, and the liberated FGFs subsequently bind to cell surface heparan sulphate proteoglycans (HPSGs) stabilizing the FGF-FGFR interaction [135].

FGFs that signal through FGFR regulate a broad spectrum of biological functions and can involve both tumor cells and the surrounding stroma. These effects include cellular proliferation, resistance to cell death, increased motility and invasiveness, enhanced metastasis as well as increased angiogenesis [134]. FGF-2, also known as basic FGF (bFGF), is the most characterized pro-angiogenic mediator in physiological conditions as well as during tumor progression [136, 137]. FGF-2 exerts its effects on endothelial cells via a paracrine signaling after being released by tumor and stromal cells or mobilized from extracellular matrix. It has been described that FGF-2 can promote angiogenesis acting together with VEGF, by inducing the secretion of MMPs, plasminogen activator and collagenase responsible for the degradation and organization of the extracellular matrix [134]. In addition, a recent study has identified FGF signaling as a key regulator of blood and lymphatic vascular development by modulating endothelial metabolism driven by MYC-dependent glycolysis, which is crucial for endothelial cell sprouting, migration and proliferation [138]. In tumors, FGF expression has been associated with resistance to anti-angiogenic therapy. Indeed, activation of the proangiogenic FGF signaling pathway has been proposed to be a mechanism that the tumor cells use to escape from VEGF-targeted therapies. A recent study performed in a murine breast cancer model shows that FGF receptor inhibition leads to decreased vessel density and restored tumor sensitivity to anti-VEGF therapy [139].

The platelet derived growth factor (PDGF) family

The PDGF family comprise four heparin-binding polypeptide growth factors denoted A, B, C, and D. PDGF is secreted by activated platelets, endothelial, epithelial, glial cells as well as inflammatory cells and it targets a broad spectrum of cell type including, fibroblasts, pericytes, smooth muscle cells, glial cells or mesangial cells [140]. PDGF signals through two cell-surface tyrosine kinase receptors, PDGFRα and PDGFRβ, and regulates many biological functions including angiogenesis, by promoting vessel maturation and recruitment of pericytes and by inducing upregulation of VEGF [141]. All members of the PDGF family display potent angiogenic activity in vivo, however, the PDGF-B/PDGFRβ axis is the most characterized. The importance of PDGF in vessel function was demonstrated by lethality of mice lacking components of the PDGF-B/PDGFRβ pathway, displaying vessel leakage and micro-hemorrhage [142].

PDGF and PDGFR are involved in cancer development and progression through autocrine stimulation of tumor cell growth and paracrine stimulation on stromal cells inducing tumor-associated angiogenesis. In an experimental model of glioma, PDGF-B enhanced angiogenesis by stimulating VEGF expression in tumor-associated endothelial cells and by recruiting pericytes in newly-formed vessels [143].


Angiopoietins (ANGPTs) are growth factors that regulate development, maintenance and remodeling of the blood vessels, and they play a key role in controlling tumor growth and angiogenesis. The human angiopoietin family comprises the ligands ANGPT-1, ANGPT-2, and ANGPT-4 [144, 145]. Angiopoietins signaling is mediated by endothelial receptor tyrosine kinases TIE-1 and TIE-2, TIE-2 being the best characterized [146].

ANGPT-1 and ANGPT-2 both bind to TIE-2, but elicit very different responses. ANGPT-1 promotes vessel maturation and stabilization of the newly-formed vessels through the Akt/survivin pathway. In contrast, ANGPT-2 has been shown to induce vessel destabilization, pericytes detachment, vessel sprouting and angiogenesis [147]. Increased ANGPT-2 expression has been observed in activated endothelial cells during inflammation and in tumor-associated vessels of several human cancers in response to hypoxia and VEGF [148]. Moreover, ANGPT-2 has been identified as an autocrine regulator of endothelial cell inflammatory response by sensitizing endothelial cells towards TNF and inducing upregulation of adhesion molecules [149].

Upregulation of ANGPT-2 in glioblastoma has been associated with reduced efficacy of anti-VEGF treatment and increased therapy resistance [150]. Preclinical studies have demonstrated beneficial effects on inhibiting tumor progression by dual inhibition of ANGPT-2/VEGFR2. Indeed, simultaneous ANGPT-2 and VEGFR2 inhibition impairs tumor growth, prolong vessel normalization and blocks macrophage recruitment improving survival of glioma bearing mice [151, 152]. Co-targeting of ANGPT-2/VEGFR2 is also effective in other murine tumor models, including early breast cancer, colorectal and renal cancer [153].

Eph/ephrin signalling

The Eph proteins belong to the superfamily of receptor tyrosine kinases and include 14 human type 1 transmembrane protein members. The Eph proteins are divided in two subgroups, EphA and EphB based on their sequence homologies and the ability to bind their ligands, the ephrins. The EphA subgroup includes nine members (EphA1-A8 and A10) and the EphB subgroup five members (EphB1-B4, B6). Unlike other tyrosine kinases whose ligands are soluble proteins, the Ephs ligands are associated with the plasma membrane of expressing cells and are classified in two subclasses based on the type of membrane binding. The ephrins A include six members (A1–A6) and are attached to the membrane by a glycosylphosphatidyl-inositol (GPI) domain. The Ephrins B are single pass type 1 transmembrane proteins and this subclass includes three members (B1–B3) [154].

A unique features of Eph receptors and their membrane anchored ligands is their ability to mediate bi-directional signals (forward and reverse signal) between adjacent cells. The “forward signal” occur when Eph/ephrin signal transduce into receptor-binding cell and the “reverse signal” when the ligand-receptor interaction leads to transduction into the ligand-expressing cell, reviewed in [155].

Ephrins and Eph receptors are involved in several processes that occur during embryogenesis including vascular development, tissue-border formation, cell migration and axon guidance [156, 157]. However, an important role Eph/ephrins system has also been found in pathological conditions such as cancer [158, 159]. Many ephrins and Eph receptors are upregulated in human tumors such as breast, colon, liver, brain, prostate and melanoma and are often associated with tumor progression and metastasis [158, 159]. On the other hand, also downregulation of Eph receptors can lead to increased metastasis as shown for EphA1 in colorectal cancer, EphA7 in prostate carcinomas, and EphB6 in melanoma [160, 161].

Several studies directly associate Eph/ephrins system to tumor angiogenesis. Ogawa et al. [162] was one of the first to report tumor vasculature-specific expression of EphA2 and ephrinA1 in blood vessels of preclinical models of breast carcinoma and Kaposi’s sarcoma. Subsequently, it was found that blocking EphA receptor signalling using soluble EphA receptors decreases tumor vascular density, tumor volume and cell proliferation [163, 164, 165].

EphB4-ephrinB2 signalling was also associated with increased tumor angiogenesis and tumor progression [166] as well as with resistance to anti-angiogenic therapy [167]. Indeed, in this preclinical study of glioma, EphB4 overexpression was associated with alterations in vascular morphogenesis, pericyte coverage, cellular proliferation and apoptosis, inducing a vascular phenotype resistant to therapy. Furthermore, a recent study identified EphrinB2 as a regulator of perivascular invasion and proliferation of glioblastoma stem-like cells [168].

Importantly, a connection between ephrins and VEGF signalling has also been shown. In particular, it was found that ephrin-B2 is able to control VEGF signalling by inducing VEGFR2 and VEGFR3 internalization, thereby regulating angiogenesis and lymphangiogenesis in physiological conditions as well as during tumor progression [169, 170].

Apelin/APLNR pathway

Apelin (APLN) is an endogenous peptide-ligand of the G protein-coupled receptor APJ (APLNR) [171]. The APLN/APLNR signaling pathway is involved in developmental angiogenesis, where the APLNR expression is predominantly restricted to the ECs of the developing vascular system and APLN regulates vascular patterning in the embryo [172, 173, 174]. APLN/APLNR signaling has key function in several physiological processes like cardiac function, angiogenesis, metabolism and body fluid homeostasis, and also in pathological conditions like heart failure, cancer, obesity and diabetes (reviewed in detail [175]).

The APLN/APLNR pathway is upregulated in malignant cells in many tumor types [174, 176, 177], as well as in tumor endothelial cells [178], and elevated Apelin levels are associated with disease progression and poor clinical outcome [176, 179, 180, 181]. Apelin expression in tumors is regulated by hypoxia [181] and is suggested to promote tumor growth in several ways. Apelin directly stimulates tumor cell proliferation [181, 182, 183], tumor cell migration and metastasis [184, 185]. Apelin also stimulates neoangiogenesis and microvascular proliferation within the tumor, leading to enhanced tumor growth [174, 176, 186, 187].

The clinical outcome of targeting APLN/APLNR pathway for cancer therapy depends on the tumor type. In models of lung and breast cancer, targeting Apelin prevented resistance associated with anti-angiogenic therapy by reducing tumor growth, metastasis and improving vessel function [188]. In models of glioma, targeting Apelin promoted invasiveness of tumor cells positive for APLNR. However, combined targeting of VEGFR2 and Apelin improved survival of glioma bearing mice [189]. In another glioma study targeting APLNR with a competitive antagonist reduced tumor growth in mice [190]. In a renal cell carcinoma study, APLNR expression in a subset of patients was found to be negatively correlated with tumor PD-L1 expression [177]. This also indicates a role of APLN/APLNR signaling in the regulation of immunological processes, which needs to be further investigated.


Chemokines are a large family of small secreted proteins with conserved cysteine residues that act through binding G-protein linked chemokine receptors with seven transmembrane structures. Depending on the number of amino acids separating the cysteine residues that make up the disulfide bonds that are required for structural integrity, chemokines are classified into CC, CXC, XC and CX3C subclasses [191]. The CXC chemokines are further divided into ELR + or ELR− groups depending on the presence or absence of a Glu-Leu-Arg motif preceding the first cysteine residue in the N-terminus, which is essential to regulate chemotaxis across endothelium. Chemokines mediate specific homing of progenitor cells and leukocytes expressing their cognate receptors. In cancer, chemokines contribute to tumor angiogenesis either directly through binding chemokine receptors expressed on endothelial cells, or indirectly through recruitment of inflammatory cells and progenitors.

ELR + CXC chemokines, including CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7 and CXCL8 enhance angiogenesis through binding to their common receptor CXCR2. CXCR2 can be expressed in microvascular endothelial cells [192], and in tumor vessels in several types of human cancer [193, 194]. Inhibition of CXCR2 decreased tumor growth and angiogenesis in a genetic murine model of pancreatic ductal adenocarcinoma [195]. In human ovarian carcinoma cells, CXCR2 activation induced angiogenesis through enhanced expression of VEGF and knockdown reduced tumorigenesis in nude mice [196]. Expression of ELR + chemokines may also induce angiogenesis indirectly, since CXCR2 can be expressed on neutrophils and is involved in leukocyte arrest prior to transendothelial migration [197]. Among the CXC ELR + chemokines, especially CXCL8 has been found to be important for tumor angiogenesis in several tumor types [198, 199]. It can support endothelial survival and induce release of pro-angiogenic factors such as VEGF, MMP-2 and MMP-9 [200, 201, 202, 203]. CXCL8 is a strong neutrophil attractant, and induces neutrophil respiratory burst upon recruitment [204].

CXCL12/SDF1 binds to CXCR4 and is the only CXC ELR- chemokine that is directly pro-angiogenic and chemotactic, while other chemokines in this group, including CXCL4, CXCL9 CXCL10, CXCL11 and CXCL14 have angiostatic effects [205]. CXCR4 is enriched in tip cells and highly expressed in tumor vessels [11, 206]. Hypoxia-induced stabilization of HIF1a leads to up-regulation of CXCL12, which in turn mediates recruitment of CXCR4-expressing endothelial progenitor cells from the bone marrow, thereby contributing to vasculogenesis [207]. In addition, CXCL12/CXCR4 is involved in vessel co-option and trafficking of leukocytes to the tumor.

CCL2 is expressed in tumors and affects endothelial permeability and metastasis through interacting with CCR2 expressed on tumor endothelial cells [208]. Endothelial progenitor cells expressing CCR2 can be recruited from the circulation in response to tumor expression of CCL2, contributing to tumor angiogenesis [209]. The necessity of CCL2 for mobilization of endothelial progenitor cells was demonstrated in a genetic murine breast cancer model, exhibiting reduced numbers of these cells in the blood in Her2/neu CCL2-deficient mice [209]. Survival of Her2/neu mice was increased by treatment with CCXC872, a small molecule antagonist targeting CCR2.

Other proangiogenic factors contribute to tumor angiogenesis

During tumor progression, expression of various matrix metalloproteases (MMPs) either by the tumor cells or by surrounding stromal cells, helps to remodel the ECM and release ECM- and membrane-bound growth factors promoting tumor progression, metastasis and tumor-associated angiogenesis. Transcription of MMPs can be induced by various signals including cytokines, growth factors, and mechanical stress. Secretion of MMP-2 and MMP-9 activate the latent form of transforming growth factor-beta (TGF-β), further promoting tumor invasion and angiogenesis [210]. TGF-β is an important regulator of neovascularization in tumor and it acts in a context-dependent manner by promoting angiogenesis via stimulation of pro-angiogenic factors like VEGF or inhibiting tumor angiogenesis by impairing endothelial cell proliferation and migration or by inducing apoptosis [211].

Tissue necrosis factor-α (TNF-α) is an inflammatory cytokine released by macrophages, mast cells and T-lymphocytes and it is also implicated in tumor progression, cell survival, differentiation, invasion, metastases as well as secretion of cytokines and pro-angiogenic factors. The effect of TNF on angiogenesis, however, is controversial. Indeed, it has been reported that depending on its temporal expression during the angiogenic process it can exert pro- or anti-angiogenic effects by regulating the expression of VEGFR2 [212].

Another pro-angiogenic factor expressed in tumors is pleiotrophin (PTN), a small heparin-binding cytokine that is abundant in the brain during embryonic development and is re-induced during pathological conditions [213]. PTN level is increased in several types of cancer including glioma, breast cancer, lung cancer, melanoma, neuroblastoma, pancreatic cancer, and prostate cancer, and may increase tumor growth either through direct effects on tumor cells or through stimulation of angiogenesis and remodeling of the tumor microenvironment [214, 215].

High levels of PTN correlates with poor survival of patients with astrocytomas and is associated with vascular abnormalities. Studies in murine glioma models have provided evidence that PTN can enhance tumor growth through stimulation of the tumor vasculature [216].

Many other factors potentially regulating angiogenesis in tumors have been identified, but have not yet been fully explored. Neurite outgrowth inhibitor or Nogo belongs to the reticulon 4 (RTN4) protein families, which consists of three major splicing isoforms (NogoA, Nogo-B, and Nogo-C) with distinct expression patterns that binds to NgR receptors [217, 218]. An essential role of Nogo-B in regulating vascular remodeling was reported in Nogo-A/B-deficient mice [219]. Mice that are deficient for Nogo-A/B exhibit reduced arteriogenesis and angiogenesis in vivo due to impaired macrophage infiltration [219, 220]. More recently it has been reported that the expression level of Nogo-B is upregulated in hepatocellular carcinoma and Nogo-B deficiency suppressed the tumor growth and metastasis [221]. The expression level of Nogo-B correlated with tumor vessel density in hepatocellular carcinoma and anti-Nogo-B antibody inhibited tumor growth in vivo via suppressing tumor angiogenesis [222].

Hypoxia or genetic alterations leading to stabilization of HIF induce tumor angiogenesis

Hyper-proliferation of tumor cells results in increased oxygen consumption, and when the tumor mass surpass the blood supply the tumor becomes hypoxic. Hypoxia induces production of pro-angiogenic factors leading to enhanced, rapid and chaotic blood vessel formation. Cellular adaptation to hypoxia is primarily mediated by a family of transcriptional regulators, hypoxia-inducible factors (HIFs). HIFs are heterodimers consisting of an oxygen-dependent α-subunit (HIF-α) and an oxygen-independent β-subunit (HIF-β). HIF-α has three isoforms, HIF-1α, HIF-2α, and HIF-3α. HIF-1α being the major responsible for activating transcriptional responses under hypoxia [223]. Hypoxia-induced stabilization of HIF-1α, promote the upregulation of several pro-angiogenic genes including VEGF, FGF and PDGF [224].

Genetic alterations in the oxygen-signaling pathway can influence the activation of HIF under normoxic condition. The von Hippel-Lindau (VHL) protein plays a central role in the oxygen-sensing pathway promoting HIFα proteosome-mediated degradation during normoxia. Mutations in this gene, resulting in the stabilization of HIF-1α and activation of the target pro-angiogenic genes is found in many tumors and it is associated with tumor progression and poor patient outcome [225].

Contributions of immune cells to tumor angiogenesis

The tumor microenvironment is comprised of a broad array of stromal cells, endothelial cells, immune and inflammatory cells. The malignant cells and cells within the tumor microenvironment continuously interact with each other to develop a dynamic and tumor-promoting milieu [226]. Notably, there is tight and mutual interplay between the immune and endothelial cells. Immune cells depend on the expression of adhesion molecules on endothelial cells for extravasation into tumor tissue, where they can exhibit their anti-tumor properties. On the other hand, immune cells are a source for several soluble factors that influence angiogenesis, endothelial cell behavior and subsequent tumor progression. The impact of different immune subsets on angiogenesis and endothelial cell remodeling is well studied [227, 228, 229]. The contribution of the most prominent immune cell types (macrophages, myeloid derived suppressor cells, neutrophils and lymphocytes) to tumor angiogenesis and endothelial cell remodeling are discussed below.


Macrophages are specialized phagocytes that clear invading microbes and cell debris, present antigens to the adaptive immune system and release various immunomodulatory cytokines. They are very plastic cells, able to exist in a range of different phenotypes based on stimuli in the tissue microenvironment [230]. The two extremes of this range are the pro-inflammatory M1 phenotype, associated with active microbial killing, and the M2 phenotype, associated with immune suppression, tissue remodeling and angiogenesis [231]. Tumor-associated macrophages (TAMs) can have different phenotypes depending on the tumor microenvironment, but generally closely resemble M2 macrophages [232].

TAMs are known to modulate and support angiogenesis. Depletion of TAMs results in the inhibition of tumor angiogenesis, whereas reconstitution of TAMs promotes angiogenesis in murine cancer models [233, 234]. Hypoxia in the tumor microenvironment simulates metabolic adaptation of TAMs and pro-angiogenic characteristics. Primarily, TAMs promote angiogenesis by producing multiple proangiogenic factors facilitating the proliferation of endothelial cells, induction of sprouting, tube formation, and maturation of new blood vessels. These factors include VEGFA, VEGFC, VEGFD, EGF, FGF2, chemokines (CXCL8, CXCL12, TNFα and MCP-1), semaphorin 4D, adrenomedullin, and thymidine phosphorylase [231, 235, 236, 237, 237]. TAMs release a number of angiogenesis-modulating molecules that include enzymes (COX-2, iNOS) [238], matrix metalloproteinases (MMPs-1, 2, 3, 9, and 12) [239], cathepsin proteases [240] and plasmin, urokinase plasminogen activator [241]. They act in synergy and trigger degradation of the basement membrane and extracellular matrix components, destabilizing the vasculature and promoting migration and proliferation of endothelial cells. TAMs can also promote angiogenesis by inhibiting the expression of angiogenesis inhibitors, such as vasohibin-2 [242]. TAMs expressing Tie2 (TEMs) have been identified to be closely associated with the blood vessel and transmit angiogenic signals at least partially by the expression of FGF-2 [80]. TEMs support vessel stability by antagonizing the effect of vascular disrupting agents and promoting tumor growth [243].

Myeloid-derived suppressor cells (MDSCs)

MDSCs are a heterogeneous population of immature myeloid cells that expand and accumulate under pathological conditions such as infection, trauma, autoimmune diseases and cancer. MDSCs are broadly classified in two sub-populations, the monocytic MDSC (M-MDSC) and granulocytic MDSC (G-MDSC), which exist both in humans and mice [244] [245]. However, there are no clear set of markers to differentiate G-MDSCs and neutrophils, and there has therefore been a debate and confusion in the field concerning the identity and relationship between these two cell types [246]. MDSC recruitment to the tumor can be induced by many different factors e.g. CSF3, IL-1β, and IL-6, and subsequently lead to activation of STAT3, rendering them potent as proangiogenic and immunosuppressive cells [247].

The capability MDSC regulating tumor angiogenesis is similar to M2-like TAMs. MDSCs promote and sustain tumor angiogenesis primarily by secretion of MMPs. In particular, MMP-9 is known to boost angiogenesis and stimulate tumor neovasculature by increasing the bioavailability of VEGF [248]. This initiates a feedforward loop as VEGF can further trigger MDSC recruitment [249]. MDSC accumulation in the tumor correlates with intra-tumoral VEGF concentration during disease progression [250]. In the presence of VEGF, MDSCs can create a pro-angiogenic milieu within the tumors by secreting angiogenic factors including CCL2, CXCL8, CXCL2, IL-1β, ANGPT1, ANGPT2, and GM-CSF [251, 252]. These chemokines can further promote MDSCs accumulation in the tumor creating a vicious circle. They also express Bv8, also known as prokineticin 2, which plays an important role in MDSC mediated angiogenesis [253]. Accumulation of MDSCs in the tumor microenvironment induces resistance to anti-angiogenic therapy [254, 255], while MDSC ablation has synergistic effects with anti-VEGF/VEGFR treatment [249, 256].


Neutrophils are the most abundant leukocyte population, providing the first line of defense against invading pathogens. They are a rich source of soluble factors such as ROS, peptides, cytokines and enzymes that exert antimicrobial activities [257]. Neutrophils are one of the main sources of VEGF and are known to play an important role during physiological angiogenesis, for example in endometrial angiogenesis during the menstrual cycle [258, 259]. Other studies have demonstrated that depletion of neutrophils affects neo-vascularization in animal models of angiogenesis [260, 261].

Conclusive evidence of neutrophils involvement in tumor angiogenesis came from studies in the RIP1-Tag2 multi-step pancreatic carcinogenesis mouse model. Neutrophil depletion using anti-GR1 antibodies reduced the number of dysplastic islets that were undergoing angiogenesis [262]. In addition, two subtypes of neutrophils have been reported at least in murine tumor models: TGFβ-independent type 1 (N1) with antimicrobial functions, and TGFβ-dependent tumor-associated neutrophils (N2, TANs) possessing pro-tumor and proangiogenic functions [263, 264]. Neutrophil survival and proliferation in tumors depend on CSF3-CSF3R mediated activation of STAT3 signaling. STAT3 activation in neutrophils triggers the angiogenic switch through secretion of VEGF, IL-8, TNF-α, MMP9, FGF2, ANGPT-1 and HGF in mice [265, 266, 267]. CSF3 is also known to stimulate neutrophils to secrete Bv8 and induce myeloid cell mobilization in tumors and promote myeloid-dependent angiogenesis [253]. MMP9-producing TANs contribute to the initiation of angiogenic switch and acceleration of tumorigenesis [262]. TANs usually lack expression of tissue inhibitors of metalloproteinases (TIMP1), rendering them more angiogenic than cells that are capable of producing TIMP1/MMP9 complexes [268].


There are three major types of lymphocytes, namely T cells and B cells, which constitute the adaptive immune system and NK cells, which are part of the innate immune system. The contribution of lymphocytes towards tumor angiogenesis is not as well understood, as that of myeloid cell types.

A subset of NK cells (CD56brightCD16KIR+, dNK cells), characterized by poor cytotoxicity and pro-angiogenic capacity have been identified in the decidua during pregnancy. They secrete VEGF, placental growth factor (PlGF), IFNγ, IL10 and CXCL8 that are critical for spiral artery formation and decidual vascularization [269, 270]. TGFβ promotes dNK cell polarization and can induce VEGF and PlGF secretion from healthy donor NK cells [271, 272]. In the presence of TGFβ, NK cells convert to type 1 innate lymphoid cells, leading to evasion of immune response and an inability to control tumor growth and metastasis [273].

The ability of B cells to modulate tumor angiogenesis depends on activation of STAT3. Transfer of B cells expressing STAT3 to Rag1−/− mice leads to enhanced tumor growth accompanied with increased angiogenesis. This is a result of an interaction between STAT3-activated B cells and endothelial cells through production of VEGF [274]. B cells also contribute to tumor angiogenesis via antibody-mediated activation of Fcγ receptors on TAMs, inducing secretion of IL-1. This leads to recruitment of myofibroblasts and promotion of tumor angiogenesis [275].

T cells promote angiogenesis by secretion of pro-angiogenic factors FGF-2 and heparin-binding epidermal-like growth factor (HB-EGF) [276]. However, the most prominent T cell derived factors, such as TNF, TGFβ, and interferons (IFNs), have anti-angiogenic functions [277, 278, 279]. The antiangiogenic effects of IFNs are mediated by direct effects on endothelial cells and other cells in the tumor microenvironment. Treatment with IFN-α/β induced necrosis of endothelial cells within tumors and decreased tumor metastases to the liver and spleen [280]. In vitro, TNF and IFNs can block collagen synthesis and extracellular matrix formation and thus inhibit the formation of capillary-like structures [281, 282]. IFN-γ can inhibit neovascularization and induce apoptosis if endothelial cells in murine glioma models [277]. Type-I polarized T cells (Th1) secrete IFNγ and their presence in the tumor microenvironment usually correlates with good clinical outcome [283]. Interferon-induced CXC family chemokines inhibit endothelial cell proliferation, promote Th1 type T cell, NK and DC infiltration, thereby inhibiting tumor growth. CXCL9, CXCL10 and CXCL11 are interferon-inducible angiostatic chemokines that can directly inhibit angiogenesis by binding CXCR3 on endothelial cells [284, 285, 286].

Anti-angiogenic therapy: successes and failures

The concept of targeting angiogenesis as a means to starve tumors was introduced by Judah Folkman and colleagues 48 years ago [1]. Since then, several antiangiogenic therapies, mainly targeting VEGF signaling pathway have been developed and approved for the treatment of a variety of tumors (Table 1). Despite promising results showed by pre-clinical studies, anti-VEGF monotherapy such as bevacizumab, sunitinib and aflibercept among others have only provided limited benefits in certain tumor types including advanced-stage renal cell carcinoma, hepatocellular carcinoma and colorectal carcinoma and have not shown efficacy in pancreatic adenocarcinoma, prostate cancer, breast cancer or melanoma [287]. Data obtained by the AVANT trial of adjuvant bevacizumab in colorectal cancer shows evidence of higher incidence of relapses and deaths in bevacizumab treated patients due to disease progression suggesting an increased tumor aggressiveness after anti-angiogenic therapy [288]. This is consistent with studies in experimental models of cancer, which correlate anti-angiogenic treatment with increased local tumor invasiveness and formation of distant metastasis [289, 290, 291, 292]. In glioma, numerous clinical studies collectively show that anti-angiogenic treatment can prolong progression-free survival but fails to improve overall survival [293]. The limited success of anti-angiogenic therapy in glioma is likely at least in part due to an escape from therapy by invasive tumor cells co-opting the vasculature of the surrounding brain tissue. Several molecular mechanisms have been identified that may explain resistance and increased invasion after anti-angiogenic therapy in glioma, including mesenchymal transition of tumor cells, up-regulation of pro-angiogenic factors, activation of MET and up-regulation of MMPs [293, 294, 295, 296]. Metastasis-promoting effects have mainly been obtained from experimental models and clear evidence from clinical studies is still lacking. The reasons underlying insufficient efficacy of vessel-targeting strategies have been extensively investigated, and include stroma and tumor cell mechanisms of resistance [287, 297].
Table 1

FDA approved anti-angiogenic drugs and their targets


Target molecule(s)

Tumor type


Monoclonal antibodies



Colorectal cancer, non-small cell lung cancer, cervical cancer, ovarian cancer, renal cell carcinoma, glioblastoma

[4, 335, 336, 337, 338, 339]



gastric or gastro-oesophageal junction cancers, colorectal cancer, hepatocellular carcinoma, non-small-cell lung carcinoma

[340, 341, 342, 343]



Squamous cell carcinoma of the head and neck, colorectal cancer

[344, 345]



Colorectal cancer




Squamous non-small-cell lung cancer




HER2-positive breast cancer, HER2-positive advanced gastric or gastro-oesophageal junction cancer

[348, 349]



HER2-positive breast cancer


Tyrosine kinase inhibitors



Hepatocellular carcinoma, renal cell carcinoma, thyroid cancer

[351, 352, 353]


VEGFR-1, VEGFR-2, VEGFR-3, PDGFR family, Kit, FLT3, CSF-1R, RET

Gastrointestinal stroma tumor, pancreatic cancer, renal cell carcinoma

[354, 355, 356]


PDGFR, c-Kit, Abl

Gastrointestinal stroma tumor, myeloid leukemia, philadelphia chromosome-positive acute lymphoblastic leukemia

[357, 358, 359]


VEGFR-1, VEGFR-2, VEGFR-3, PDGFR family, Kit, Itk, LcK, c-FMS

Renal cell carcinoma, soft tissue sarcoma

[360, 361]



Non-small cell lung cancer




Non-small cell lung cancer, pancreatic adenocarcinoma

[363, 364]


VEGFR-2, FGFR family, RET, BRT, Tie-2,EPH, Src family

Medullary thyroid cancer




Colorectal cancer, Gastrointestinal stroma tumor, hepatocellular carcinoma

[366, 367, 368]



HER-2 positive breast cancer




HER-2 positive breast cancer




Non-small cell lung cancer



VEGFR-1, VEGFR-2, VEGFR-3, PDGFR family, Kit

Renal cell carcinoma



VEGFR-2, c-Met

Hepatocellular carcinoma, medullary thyroid cancer, renal cell carcinoma

[373, 374, 375]



Hepatocellular carcinoma, thyroid cancer

[376, 377]

Receptor fusion proteins

 Ziv-aflibercept (VEGF trap)


Colorectal cancer


Immunomodulatory agents with anti-angiogenic effect



Multiple myeloma




Multiple myeloma


mTOR inhibitor with anti-angiogenic effect



Renal cell carcinoma, breast cancer, pancreatic cancer, gastrointestinal cancer, lung neuroendocrine tumor, subependymal giant cell astrocytoma

[381, 382, 383, 384, 385]

Mechanisms of resistance to anti-angiogenic therapy

Resistance to anti-angiogenic therapy is an important issue that likely explains the variable response in different types of tumors and the limited overall survival benefits. Resistance can be classified into intrinsic resistance, observed from the outset of the therapy, and acquired resistance, observed after an initial positive response to therapy [297]. Several mechanisms have been proposed for anti-angiogenic therapy resistance, including direct effects of hypoxia such as induction of tumor invasion and metastasis, co-option of normal vessels in the surrounding tissue, vascular mimicry as well as the contribution of stromal cells including recruitment of TAMs, EPC and pro-angiogenic myeloid cells as well as the upregulation of alternative pro-angiogenic factors [297] [298].

As already mentioned, anti-angiogenic therapy can promote tumor invasion and metastasis in pre-clinical cancer models, which might be triggered by increased hypoxia due to vessel depletion. Indeed, the transcription of HIF-regulated genes controls different steps of tumor invasion and metastasis, including EMT, activation of MET signaling, recruitment of stromal cells, vascular mimicry and vessel co-option [299]. Vessel co-option is defined as a non-angiogenic process whereby tumor cells directly utilize the pre-existing vasculature of the non-malignant tissue as a supply of oxygen and nutrients, resulting in resistance to anti-angiogenic therapy [5]. The first evidence of vessel co-option as a mechanism of acquired resistance to anti-angiogenic therapy was demonstrated by a study in a mouse model of hepatocellular carcinoma investigating the response to sorafenib treatment [300]. In addition to vessel co-option, tumor cells can develop vascular mimicry as an alternative blood transportation system to counteract the lack of oxygen and nutrient upon anti-angiogenic therapy. Indeed, preclinical studies conducted in renal carcinoma model reported that the VEGFR2 inhibitor sunitinib increases vascular mimicry under hypoxia by transforming tumor cells into endothelial-like cells resulting in tumor resistance [301].

Recruitment of stromal cells, immune cells and progenitors is another potential mechanism for resistance to anti-angiogenic therapy. In particular, many studies have pointed out an important role of bone marrow derived cells (BMDCs) in this aspect. Recruitment of BMDCs in glioblastoma can cause resistance to vatalanib treatment and the depletion of BMDCs can potentiate the effects of this anti-angiogenic drug [302]. Release of proangiogenic factors and increased hypoxia in response to vascularization blockade can lead to recruitment of endothelial progenitor cells (EPC) from the bone marrow, which contribute to tumor vascularization and have been linked to development of resistance to anti-VEGF therapy [303]. Moreover, recruitment of pro-angiogenic myeloid cells is also considered to be a mechanism whereby tumors bypass the inhibitory effects of anti-angiogenics drugs. Tumors can recruit different populations of myeloid cells with pro-angiogenic properties which in turn can be used as an alternative source of pro-angiogenic chemokines and cytokines [304].

In addition, alternative pro-angiogenic signaling pathways including ANGPT-2, FGF-2, IL-8 can be induced by tumor cells in response to a pharmacological inhibition of the VEGF signaling pathway [297]. In recent years, progress has been made towards understanding the mechanism of action of anti-angiogenic drugs through evaluating the effects of anti-angiogenic inhibitors on tumor vessels in preclinical and clinical studies. An important aspect that have emerged is the broad spectrum of effects covered by the angiogenic inhibitors and the diversity in terms of therapeutic response [305].

Mechanisms mediating the therapeutic effect of angiogenesis inhibitors

Although anti-angiogenic drugs were initially designed to block blood vessel formation, their ability to control tumor growth may be due to several different mechanism, which are not mutually exclusive. To improve vascular targeting, a thorough understanding of the cellular and molecular mechanisms that hinder tumor progression in response to anti-angiogenic therapy in specific tumors is necessary. The possible mechanism of actions of angiogenesis inhibitors on tumor blood vessels can be broadly classified into three categories: (a) vessel depletion, (b) vessel normalization, and (c) immune activation (Fig. 3).
Fig. 3

Effects of anti-angiogenic therapy. The mechanism of actions of angiogenesis inhibitors on tumor blood vessels can be classified into three categories: a vessel depletion, b vessel normalization, and c immune activation. a Vessel depletion result in tumor cell starvation and an increased tissue hypoxia. Enhanced hypoxia may promote the recruitment of pro-angiogenic myeloid cells and the mobilization of tumor cell from the hypoxic tissue to the normal tissue as well as co-option of normal vessels. In addition, the depletion of tumor vessels results in an inefficient delivery of anti-cancer drugs. b Normalization of tumor blood vessels achieved by restored endothelial cell junctions, increased pericytes coverage and re-established blood flow result in decrease tissue hypoxia and increased drugs delivery. In addition, vessel normalization promote the expression of endothelial adhesion molecule facilitating immune cell infiltration. c Immune activation, induced by anti-angiogenic drugs include dendritic cell (DC) maturation, activation and infiltration of T-cell as well as the polarization of tumor associated macrophages (TAM) towards an M1-like phenotype. In addition, a decrease in regulatory T-cells (Treg), myeloid derived suppressor cells (MDSCs) and mast cells have been observed in response to anti-angiogenic therapy

Vessel depletion

The development of anti-angiogenic drugs was initiated by the hypothesis that starving tumors by blocking angiogenesis would slow tumor progression and improve patient survival [1]. Early preclinical studies were promising and demonstrated a significant tumor growth delay and reduced metastasis. However, the effects of anti-angiogenic agents administrated as monotherapy in cancer patients during clinical trials often failed to show significant survival benefits. These observations suggest that anti-angiogenic therapy alone is insufficient to induce substantial tumor shrinkage in most cancer patients. Particular attention must be placed on the effects of tumor vessel depletion on the tumor microenvironment as well as the development of anti-angiogenic resistance. Indeed, as mentioned above, hypoxia induced by vessel depletion can activate several mechanisms used by tumor cells to counteract the lack of oxygen and nutrients such as increased tumor invasiveness and co-option of normal vessels resulting in ineffective anti-angiogenic therapy.

Several studies demonstrate that before reaching complete depletion of the vascular bed, anti-VEGF drugs induce an early and transient phase in which vessels assume normal shape and function [306, 307]. This vessel normalization window is characterized by a rescue of the balance between pro- and anti-angiogenic factors and it can promote increase tumor drug delivery and efficacy.

Vessel normalization

Despite a high vascular density, tumors are usually hypoxic and nutrient-deprived since the tumor vessels are abnormal, leaky and malfunction. Such abnormal vasculature significantly compromises the efficacy of most anti-cancer therapies by limiting the delivery of drugs as well as promoting resistance to treatment.

The vessel normalization hypothesis, introduced by Rakesh Jain in 2001 [308] suggests that rather than depleting vessels, a sub-maximal doses of anti-angiogenic therapy can restore the normal function and structure of tumor vessels and improve drug delivery. This hypothesis could explain the increased progression-free survival observed in patients treated with anti-angiogenic drugs combined with chemotherapy as compared to treatment with chemotherapy alone [309]. Evidence supporting the idea that vessel normalization can improve cancer therapy has been obtained in mouse models. These studies show that improving tumor vessel perfusion and oxygenation ameliorates the efficacy of conventional therapies such as radiotherapy, chemotherapy and immunotherapy and reduces metastatic dissemination [309, 310].

Evidence that support the notion that vessel normalization occur in response to anti-angiogenic therapy has also been obtained from clinical studies. The functionality of the tumor vasculature in glioblastoma patients treated with anti-VEGF therapies has been evaluated by magnetic resonance imaging (MRI). MRI analysis of patients treated with cediranib revealed a decrease in vessel diameter, vascular permeability, and edema. More importantly, survival of patients with recurrent glioblastoma following cediranib-treatment was found to correlate with a vascular normalization index [311]. Improved perfusion occurred only in a subset of glioblastoma patients treated with cediranib, and was associated with improved patient overall survival [312]. These observations suggest that the degree of vessel normalization in terms of improved perfusion may be used as a tool to distinguish responders to anti-angiogenic therapy from non-responding patients [312, 313].

Immune activation

Pro-angiogenic factors in tumors induce down-regulation of adhesion molecules on endothelial cells in the tumor vasculature and induce anergy to inflammatory signals such as TNFα and IL-1. Hereby, tumors with an angiogenic phenotype may escape the infiltration of cytotoxic leukocytes [111]. Using anti-angiogenic agents can potentially overcome the down-regulation of adhesion molecules and the unresponsiveness to inflammatory signals [314]. Consistent with this, normalization of tumor vasculature through anti-VEGF therapy in combination with adoptive T-cell transfer was found to increase tumor T-cell infiltration and improve survival in murine melanoma model [314].

Inhibition of VEGF signaling in the tumor microenvironment may be beneficial not only in terms of improving immune cell recruitment, but can also directly improve immune cell activation. Normalization of the tumor vascular network and decreased hypoxia can promote T cell infiltration and induce polarization of TAM to an M1-like phenotype [315]. Anti-angiogenic therapy can also reduce the prevalence of immunosuppressive cells. Decreases in Treg recruitment as well as MDSC has been reported after sunitinib treatment in tumor-bearing mice and in patients with metastatic renal carcinoma [316, 317]. In addition, inhibition of angiogenic signaling may improve T-cell priming and activation by improving dendritic cell (DC) maturation. Anti-anigogenic therapy using the VEGF-neutralizing antibody bevacizumab was found to increase the number and the maturation of DCs in patients with metastatic non-small cell lung carcinoma [318]. These observations indicate that immune activation is an additional mechanism that can contribute to response to anti-angiogenic therapy.

Concluding remarks—arising opportunities for vascular targeting in cancer

Tumor vessels are often dysfunctional and anergic to inflammatory stimuli, leading to a hostile tumor microenvironment that fuel cancer progression and aggravate therapeutic approaches. Current vascular targeting strategies are based on inhibition of key angiogenic signaling pathways known to promote tumor angiogenesis. Although several anti-angiogenic drugs have been approved, intrinsic and acquired resistance to therapy limit their efficacy. An increased understanding of tumor vessel phenotype and mechanisms involved in treatment response and resistance to therapy is necessary to overcome the hurdles that prevent successful control of the angiogenic response in tumors. Alternatively, vascular targeting should instead be designed to target the tumor vessels in new ways that are conceptually different from inhibition of angiogenesis. This may involve altering the timing and dosing of already existing anti-angiogenic therapy in combination with other drugs, or development of novel therapeutics to either directly target the tumor vessels or optimize their function to fit the cancer therapy at hand.

Differential gene expression in tumor vessels provides new tools for vascular targeting

The fact that tumor vessels differ molecularly from their normal counterparts can be used to develop treatment strategies that specifically target malignant cells and tumor vasculature. Therapeutic vaccination strategies to raise endogenous antibodies against antigens specifically expressed by tumor vasculature have shown efficacy in pre-clinical cancer models [319]. Prophylactic immunization of the alternatively spliced extra domain (ED)-B of fibronectin efficiently reduced growth of syngeneic subcutaneous tumors [320], and therapeutic vaccination against ED-A after tumor development reduced metastatic dissemination in the MMTV-PyMT model of metastatic mammary carcinoma [321]. Antibodies targeting tumor vessel markers have also been used. Blocking the tumor endothelial marker TEM8/anthrax toxin receptor 1 using antibodies raised against the extracellular domain inhibited angiogenesis, decreased growth of human tumor xenografts and increased the effect of anticancer drugs [322]. Conjugating TEM8-targeting antibodies with cytotoxic monomethyl auristatin E was successful in specifically directing the drug to the tumor microenvironment of orthotopic tumors and patient derived xenografts, significantly inducing regression or eradication of tumor growth in pre-clinical models [323]. Using an alternative strategy, targeting tumor endothelium and TEM8-positive malignant cells by employing TEM8-specific CAR T cells was effective in treating triple negative breast cancer (TNBC) patient derived xenograft (PDX) models and metastatic TNBC cell-line xenografts [324]. Peptides that specifically bind tumor endothelial cells have also been used to target either therapeutic antibodies or chemokines to the tumor microenvironment to improve efficacy and decrease toxicity [325, 326].

Tailoring tumor vessels to optimize cancer therapy

Going beyond anti-angiogenesis and vascular normalization, strategies that can alter vessel phenotype to optimize specific types of cancer therapy are quickly emerging. It is already established that targeting VEGF/VEGFR signaling can enhance the efficacy of cancer immunotherapy by increasing expression of adhesion molecules and chemokines necessary for capture and transendothelial migration of T-cells [327, 328]. Several clinical trials have been initiated aimed at improving immunotherapy by combining checkpoint inhibitors with vascular targeting ( [327, 328]. To provide an even more efficient gateway for T-cells to enter the tumor microenvironment, tumor vessels can be induced to differentiate to high-endothelial venules (HEV). HEV have a distinct morphology, built up by cuboidal endothelial cells, and they express chemokine and adhesion molecules that mediate efficient recruitment of lymphocytes into the tissue [329]. Depletion of Tregs in a model of fibrosarcoma led to HEV neogenesis, enabling recruitment of T-cells into the tumor [330]. The presence of HEV within the tumor was a pre-requisite for tumor control after Treg depletion. Subsequently, it was found that activated CD8+ T cells induced HEV development within the tumor after Treg depletion [331]. Consistent with a role of activated T-cells in HEV neogenesis, combining anti-angiogenic therapy with anti-PD-L1 immunotherapy was sufficient to induce HEVs in several orthotopic and genetically engineered mouse models of cancer, stimulating tumor immunity [332]. Specific targeting of LIGHT/TNFSF14 to tumor vessels using vascular targeting peptides improved vessel functionality, activated endothelial cells and induced formation of HEV in murine glioblastoma, associated with enhanced accumulation of lymphocytes [333]. With respect to brain tumors, strategies that transiently open the blood brain barrier to enable delivery of drugs are of considerable interest [334]. The observation that paracrine signaling in WNT-medulloblastoma was associated with fenestrated tumor vessels that lack ABC transporters suggests that brain tumor vessels can indeed be modulated to allow a better penetration of drugs [117]. This exciting possibility has yet to be explored therapeutically. It is necessary to gain a deeper understanding of how tumor vessel function is altered in specific cancer types, and how vessel phenotype can be modulated. This may lead to new vascular targeting strategies aimed at tailoring vessel function to optimize drug response.



Open access funding provided by Uppsala University. Swedish Cancer Society (CAN 2017/502), the Swedish Childhood Cancer Society (PR2018-0148), the Swedish Research Council (Dnr 2016-02495), Emil and Wera Cornells Stiftelse foundation. AD was supported by a Senior Investigator Award from the Swedish Cancer Society. Mohanraj Ramachandran was supported by a postdoc position from the Swedish Childhood Cancer Society.


  1. 1.
    Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–1186PubMedCrossRefGoogle Scholar
  2. 2.
    Folkman J et al (1971) Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133(2):275–288PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Cao Y et al (2011) Forty-year journey of angiogenesis translational research. Sci Transl Med 3(114):114rv3PubMedCrossRefGoogle Scholar
  4. 4.
    Hurwitz H et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342PubMedCrossRefGoogle Scholar
  5. 5.
    Kuczynski EA et al (2019) Vessel co-option in cancer. Nat Rev Clin Oncol 16(8):469–493PubMedCrossRefGoogle Scholar
  6. 6.
    Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3):353–364PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Hanahan D (1985) Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315(6015):115–122PubMedCrossRefGoogle Scholar
  8. 8.
    Nowak-Sliwinska P et al (2018) Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis 21(3):425–532PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Jakobsson L, Bentley K, Gerhardt H (2009) VEGFRs and Notch: a dynamic collaboration in vascular patterning. Biochem Soc Trans 37(Pt 6):1233–1236PubMedCrossRefGoogle Scholar
  10. 10.
    Tammela T et al (2008) Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454(7204):656–660PubMedCrossRefGoogle Scholar
  11. 11.
    Strasser GA, Kaminker JS, Tessier-Lavigne M (2010) Microarray analysis of retinal endothelial tip cells identifies CXCR11 as a mediator of tip cell morphology and branching. Blood 115(24):5102–5110PubMedCrossRefGoogle Scholar
  12. 12.
    Shawber CJ et al (2007) Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression. J Clin Invest 117(11):3369–3382PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Jakobsson L et al (2010) Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat Cell Biol 12(10):943–953PubMedCrossRefGoogle Scholar
  14. 14.
    Hellstrom M et al (2007) Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445(7129):776–780CrossRefGoogle Scholar
  15. 15.
    Lobov IB et al (2007) Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci USA 104(9):3219–3224PubMedCrossRefGoogle Scholar
  16. 16.
    Harrington LS et al (2008) Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvasc Res 75(2):144–154PubMedCrossRefGoogle Scholar
  17. 17.
    Funahashi Y et al (2010) Notch regulates the angiogenic response via induction of VEGFR-1. J Angiogenes Res 2(1):3PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Gerhardt H et al (2003) VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161(6):1163–1177PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Fantin A et al (2013) NRP1 acts cell autonomously in endothelium to promote tip cell function during sprouting angiogenesis. Blood 121(12):2352–2362PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Segarra M et al (2012) Semaphorin 6A regulates angiogenesis by modulating VEGF signaling. Blood 120(19):4104–4115PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Phng LK et al (2009) Nrarp coordinates endothelial Notch and Wnt signaling to control vessel density in angiogenesis. Dev Cell 16(1):70–82PubMedCrossRefGoogle Scholar
  22. 22.
    Herwig L et al (2011) Distinct cellular mechanisms of blood vessel fusion in the zebrafish embryo. Curr Biol 21(22):1942–1948PubMedCrossRefGoogle Scholar
  23. 23.
    Kochhan E et al (2013) Blood flow changes coincide with cellular rearrangements during blood vessel pruning in zebrafish embryos. PLoS One 8(10):e75060PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Lenard A et al (2015) Endothelial cell self-fusion during vascular pruning. PLoS Biol 13(4):e1002126PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Lenard A et al (2013) In vivo analysis reveals a highly stereotypic morphogenetic pathway of vascular anastomosis. Dev Cell 25(5):492–506PubMedCrossRefGoogle Scholar
  26. 26.
    Phng LK, Stanchi F, Gerhardt H (2013) Filopodia are dispensable for endothelial tip cell guidance. Development 140(19):4031–4040PubMedCrossRefGoogle Scholar
  27. 27.
    Blum Y et al (2008) Complex cell rearrangements during intersegmental vessel sprouting and vessel fusion in the zebrafish embryo. Dev Biol 316(2):312–322PubMedCrossRefGoogle Scholar
  28. 28.
    Betz C et al (2016) Cell behaviors and dynamics during angiogenesis. Development 143(13):2249–2260PubMedCrossRefGoogle Scholar
  29. 29.
    Patan S et al (1992) Intussusceptive microvascular growth: a common alternative to capillary sprouting. Arch Histol Cytol 55(Suppl):65–75PubMedCrossRefGoogle Scholar
  30. 30.
    Burri PH, Tarek MR (1990) A novel mechanism of capillary growth in the rat pulmonary microcirculation. Anat Rec 228(1):35–45PubMedCrossRefGoogle Scholar
  31. 31.
    Hellstrom M et al (1999) Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126(14):3047–3055PubMedGoogle Scholar
  32. 32.
    Wilting J et al (1996) VEGF121 induces proliferation of vascular endothelial cells and expression of flk-1 without affecting lymphatic vessels of chorioallantoic membrane. Dev Biol 176(1):76–85PubMedCrossRefGoogle Scholar
  33. 33.
    Crivellato E et al (2004) Recombinant human erythropoietin induces intussusceptive microvascular growth in vivo. Leukemia 18(2):331–336PubMedCrossRefGoogle Scholar
  34. 34.
    Ribatti D et al (2005) Microvascular density, vascular endothelial growth factor immunoreactivity in tumor cells, vessel diameter and intussusceptive microvascular growth in primary melanoma. Oncol Rep 14(1):81–84PubMedGoogle Scholar
  35. 35.
    Nico B et al (2010) Intussusceptive microvascular growth in human glioma. Clin Exp Med 10(2):93–98PubMedCrossRefGoogle Scholar
  36. 36.
    Patan S, Munn LL, Jain RK (1996) Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Microvasc Res 51(2):260–272PubMedCrossRefGoogle Scholar
  37. 37.
    Djonov V et al (2001) MMP-19: cellular localization of a novel metalloproteinase within normal breast tissue and mammary gland tumours. J Pathol 195(2):147–155PubMedCrossRefGoogle Scholar
  38. 38.
    Risau W et al (1988) Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies. Development 102(3):471–478PubMedGoogle Scholar
  39. 39.
    Risau W, Lemmon V (1988) Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesis. Dev Biol 125(2):441–450PubMedCrossRefGoogle Scholar
  40. 40.
    Choi K (1998) Hemangioblast development and regulation. Biochem Cell Biol 76(6):947–956PubMedCrossRefGoogle Scholar
  41. 41.
    Asahara T et al (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275(5302):964–967PubMedCrossRefGoogle Scholar
  42. 42.
    Bussolati B, Grange C, Camussi G (2011) Tumor exploits alternative strategies to achieve vascularization. FASEB J 25(9):2874–2882PubMedCrossRefGoogle Scholar
  43. 43.
    Kioi M et al (2010) Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 120(3):694–705PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Ahn JB et al (2010) Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients. Cancer Lett 288(1):124–132PubMedCrossRefGoogle Scholar
  45. 45.
    Greenfield JP, Cobb WS, Lyden D (2010) Resisting arrest: a switch from angiogenesis to vasculogenesis in recurrent malignant gliomas. J Clin Invest 120(3):663–667PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Chopra H et al (2018) Insights into endothelial progenitor cells: origin, classification, potentials, and prospects. Stem Cells Int 2018:9847015PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Schmidt A, Brixius K, Bloch W (2007) Endothelial precursor cell migration during vasculogenesis. Circ Res 101(2):125–136PubMedCrossRefGoogle Scholar
  48. 48.
    Romagnani P et al (2005) CD14 + CD34low cells with stem cell phenotypic and functional features are the major source of circulating endothelial progenitors. Circ Res 97(4):314–322PubMedCrossRefGoogle Scholar
  49. 49.
    Shin JW et al (2005) Isolation of endothelial progenitor cells from cord blood and induction of differentiation by ex vivo expansion. Yonsei Med J 46(2):260–267PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Urbich C, Dimmeler S (2004) Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 95(4):343–353PubMedCrossRefGoogle Scholar
  51. 51.
    Reale A et al (2016) Functional and biological role of endothelial precursor cells in tumour progression: a new potential therapeutic target in haematological malignancies. Stem Cells Int 2016:7954580PubMedCrossRefGoogle Scholar
  52. 52.
    Asahara T et al (1999) VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18(14):3964–3972PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Hattori K et al (2001) Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 193(9):1005–1014PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Kopp HG, Ramos CA, Rafii S (2006) Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. Curr Opin Hematol 13(3):175–181PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Chang EI et al (2007) Hypoxia, hormones, and endothelial progenitor cells in hemangioma. Lymphat Res Biol 5(4):237–243PubMedCrossRefGoogle Scholar
  56. 56.
    Spring H et al (2005) Chemokines direct endothelial progenitors into tumor neovessels. Proc Natl Acad Sci USA 102(50):18111–18116PubMedCrossRefGoogle Scholar
  57. 57.
    Nakamura N et al (2009) Adiponectin promotes migration activities of endothelial progenitor cells via Cdc42/Rac1. FEBS Lett 583(15):2457–2463PubMedCrossRefGoogle Scholar
  58. 58.
    Maniotis AJ et al (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155(3):739–752PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Ricci-Vitiani L et al (2010) Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468(7325):824–828PubMedCrossRefGoogle Scholar
  60. 60.
    Upile T et al (2011) Vascular mimicry in cultured head and neck tumour cell lines. Head Neck Oncol 3:55PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Williamson SC et al (2016) Vasculogenic mimicry in small cell lung cancer. Nat Commun 7:13322PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Baeten CI et al (2009) Prognostic role of vasculogenic mimicry in colorectal cancer. Dis Colon Rectum 52(12):2028–2035PubMedCrossRefGoogle Scholar
  63. 63.
    Sharma N et al (2002) Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate 50(3):189–201PubMedCrossRefGoogle Scholar
  64. 64.
    Fausto N (2000) Vasculogenic mimicry in tumors. Fact or artifact? Am J Pathol 156(2):359PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Seftor RE et al (2012) Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am J Pathol 181(4):1115–1125PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Folberg R, Maniotis AJ (2004) Vasculogenic mimicry. APMIS 112(7–8):508–525PubMedCrossRefGoogle Scholar
  67. 67.
    Angara K, Borin TF, Arbab AS (2017) Vascular mimicry: a novel neovascularization mechanism driving anti-angiogenic therapy (AAT) resistance in glioblastoma. Transl Oncol 10(4):650–660PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Valyi-Nagy K et al (2012) Stem cell marker CD271 is expressed by vasculogenic mimicry-forming uveal melanoma cells in three-dimensional cultures. Mol Vis 18:588–592PubMedPubMedCentralGoogle Scholar
  69. 69.
    Lin AY et al (2005) Distinguishing fibrovascular septa from vasculogenic mimicry patterns. Arch Pathol Lab Med 129(7):884–892PubMedGoogle Scholar
  70. 70.
    Comito G et al (2011) HIF-1alpha stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. Free Radic Biol Med 51(4):893–904PubMedCrossRefGoogle Scholar
  71. 71.
    Angara K et al (2017) Vascular mimicry in glioblastoma following anti-angiogenic and anti-20-HETE therapies. Histol Histopathol 32(9):917–928PubMedGoogle Scholar
  72. 72.
    Li M et al (2010) Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma. Pathol Oncol Res 16(2):259–266PubMedCrossRefGoogle Scholar
  73. 73.
    Wang R et al (2010) Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468(7325):829–833PubMedCrossRefGoogle Scholar
  74. 74.
    Mei X et al (2017) Glioblastoma stem cell differentiation into endothelial cells evidenced through live-cell imaging. Neuro Oncol 19(8):1109–1118PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Bussolati B et al (2009) Endothelial cell differentiation of human breast tumour stem/progenitor cells. J Cell Mol Med 13(2):309–319PubMedCrossRefGoogle Scholar
  76. 76.
    Alvero AB et al (2009) Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells 27(10):2405–2413PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Zhao Y et al (2010) Endothelial cell transdifferentiation of human glioma stem progenitor cells in vitro. Brain Res Bull 82(5–6):308–312PubMedCrossRefGoogle Scholar
  78. 78.
    Kulla A et al (2003) Analysis of the TP53 gene in laser-microdissected glioblastoma vasculature. Acta Neuropathol 105(4):328–332PubMedGoogle Scholar
  79. 79.
    Rodriguez FJ et al (2012) Neoplastic cells are a rare component in human glioblastoma microvasculature. Oncotarget 3(1):98–106PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    De Palma M et al (2005) Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8(3):211–226PubMedCrossRefGoogle Scholar
  81. 81.
    Cheng L et al (2013) Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153(1):139–152PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Baluk P, Hashizume H, McDonald DM (2005) Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15(1):102–111PubMedCrossRefGoogle Scholar
  83. 83.
    McDonald DM, Baluk P (2005) Imaging of angiogenesis in inflamed airways and tumors: newly formed blood vessels are not alike and may be wildly abnormal: Parker B. Francis lecture. Chest 128(6 Suppl):602S–608SPubMedCrossRefGoogle Scholar
  84. 84.
    Kimura H et al (1996) Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 56(23):5522–5528PubMedGoogle Scholar
  85. 85.
    Bennewith KL, Durand RE (2004) Quantifying transient hypoxia in human tumor xenografts by flow cytometry. Cancer Res 64(17):6183–6189PubMedCrossRefGoogle Scholar
  86. 86.
    Hashizume H et al (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156(4):1363–1380PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Padera TP et al (2004) Pathology: cancer cells compress intratumour vessels. Nature 427(6976):695PubMedCrossRefGoogle Scholar
  88. 88.
    Abramsson A et al (2002) Analysis of mural cell recruitment to tumor vessels. Circulation 105(1):112–117PubMedCrossRefGoogle Scholar
  89. 89.
    Morikawa S et al (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160(3):985–1000PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Baluk P et al (2003) Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 163(5):1801–1815PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    St Croix B et al (2000) Genes expressed in human tumor endothelium. Science 289(5482):1197–1202PubMedCrossRefGoogle Scholar
  92. 92.
    Zhang L et al (2003) Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 63(12):3403–3412PubMedGoogle Scholar
  93. 93.
    Carson-Walter EB et al (2001) Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 61(18):6649–6655PubMedGoogle Scholar
  94. 94.
    Huang X et al (2010) Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J Exp Med 207(3):505–520PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Dieterich LC et al (2012) Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF-A and TGFbeta2 in vascular abnormalization. J Pathol 228(3):378–390PubMedCrossRefGoogle Scholar
  96. 96.
    Roudnicky F et al (2013) Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res 73(3):1097–1106PubMedCrossRefGoogle Scholar
  97. 97.
    Zhao Q et al (2018) Single-cell transcriptome analyses reveal endothelial cell heterogeneity in tumors and changes following antiangiogenic treatment. Cancer Res 78(9):2370–2382PubMedCrossRefGoogle Scholar
  98. 98.
    Buckanovich RJ et al (2007) Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 25(7):852–861PubMedCrossRefGoogle Scholar
  99. 99.
    Zhang L et al (2018) IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas. Neuro Oncol 20(11):1505–1516PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Masiero M et al (2013) A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell 24(2):229–241PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Hanly AM, Winter DC (2007) The role of thrombomodulin in malignancy. Semin Thromb Hemost 33(7):673–679PubMedCrossRefGoogle Scholar
  102. 102.
    Maruno M et al (1994) Expression of thrombomodulin in astrocytomas of various malignancy and in gliotic and normal brains. J Neurooncol 19(2):155–160PubMedCrossRefGoogle Scholar
  103. 103.
    Mura M et al (2012) Identification and angiogenic role of the novel tumor endothelial marker CLEC14A. Oncogene 31(3):293–305PubMedCrossRefGoogle Scholar
  104. 104.
    Langenkamp E et al (2015) Elevated expression of the C-type lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival. Cancer Res 75(21):4504–4516PubMedCrossRefGoogle Scholar
  105. 105.
    Lugano R et al (2018) CD93 promotes beta1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis. J Clin Invest 128(8):3280–3297PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Christian S et al (2008) Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells. Am J Pathol 172(2):486–494PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Khan KA et al (2017) Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface. Oncogene 36(44):6097–6108PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Galvagni F et al (2017) Dissecting the CD93-Multimerin 2 interaction involved in cell adhesion and migration of the activated endothelium. Matrix Biol 64:112–127PubMedCrossRefGoogle Scholar
  109. 109.
    Mogler C et al (2015) Hepatic stellate cell-expressed endosialin balances fibrogenesis and hepatocyte proliferation during liver damage. EMBO Mol Med 7(3):332–338PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Viski C et al (2016) Endosialin-expressing pericytes promote metastatic dissemination. Cancer Res 76(18):5313–5325PubMedCrossRefGoogle Scholar
  111. 111.
    Griffioen AW et al (1996) Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 88(2):667–673PubMedCrossRefGoogle Scholar
  112. 112.
    Griffioen AW et al (1996) Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res 56(5):1111–1117PubMedGoogle Scholar
  113. 113.
    Dirkx AE et al (2003) Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res 63(9):2322–2329PubMedGoogle Scholar
  114. 114.
    Huang H et al (2015) VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-kappaB-induced endothelial activation. FASEB J 29(1):227–238PubMedCrossRefGoogle Scholar
  115. 115.
    Motz GT et al (2014) Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 20(6):607–615PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Buckanovich RJ et al (2008) Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 14(1):28–36PubMedCrossRefGoogle Scholar
  117. 117.
    Phoenix TN et al (2016) Medulloblastoma genotype dictates blood brain barrier phenotype. Cancer Cell 29(4):508–522PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669–676PubMedCrossRefGoogle Scholar
  119. 119.
    Apte RS, Chen DS, Ferrara N (2019) VEGF in signaling and disease: beyond discovery and development. Cell 176(6):1248–1264PubMedCrossRefGoogle Scholar
  120. 120.
    Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25(4):581–611PubMedCrossRefGoogle Scholar
  121. 121.
    Claesson-Welsh L, Welsh M (2013) VEGFA and tumour angiogenesis. J Intern Med 273(2):114–127PubMedCrossRefGoogle Scholar
  122. 122.
    Takahashi T et al (2001) A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J 20(11):2768–2778PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Jiang BH, Liu LZ (2009) PI3 K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 102:19–65PubMedPubMedCentralCrossRefGoogle Scholar
  124. 124.
    Lamalice L, Le Boeuf F, Huot J (2007) Endothelial cell migration during angiogenesis. Circ Res 100(6):782–794PubMedCrossRefGoogle Scholar
  125. 125.
    van Hinsbergh VW, Koolwijk P (2008) Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc Res 78(2):203–212PubMedCrossRefGoogle Scholar
  126. 126.
    Weis SM, Cheresh DA (2005) Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437(7058):497–504PubMedCrossRefGoogle Scholar
  127. 127.
    Azzi S, Hebda JK, Gavard J (2013) Vascular permeability and drug delivery in cancers. Front Oncol 3:211PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Weis S et al (2004) Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 167(2):223–229PubMedPubMedCentralCrossRefGoogle Scholar
  129. 129.
    Hofer E, Schweighofer B (2007) Signal transduction induced in endothelial cells by growth factor receptors involved in angiogenesis. Thromb Haemost 97(3):355–363PubMedPubMedCentralCrossRefGoogle Scholar
  130. 130.
    Autiero M et al (2003) Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 9(7):936–943PubMedCrossRefGoogle Scholar
  131. 131.
    Schomber T et al (2007) Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during beta cell carcinogenesis. Cancer Res 67(22):10840–10848PubMedCrossRefGoogle Scholar
  132. 132.
    Fischer C et al (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131(3):463–475PubMedCrossRefGoogle Scholar
  133. 133.
    Bais C et al (2010) PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 141(1):166–177PubMedCrossRefGoogle Scholar
  134. 134.
    Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10(2):116–129PubMedCrossRefGoogle Scholar
  135. 135.
    Ornitz DM, Itoh N (2015) The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol 4(3):215–266PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Presta M et al (2005) Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 16(2):159–178PubMedCrossRefGoogle Scholar
  137. 137.
    Compagni A et al (2000) Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res 60(24):7163–7169PubMedGoogle Scholar
  138. 138.
    Yu P et al (2017) FGF-dependent metabolic control of vascular development. Nature 545(7653):224–228PubMedPubMedCentralCrossRefGoogle Scholar
  139. 139.
    Incio J et al (2018) Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. Sci Transl Med 10(432):eaag0945PubMedPubMedCentralCrossRefGoogle Scholar
  140. 140.
    Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79(4):1283–1316PubMedCrossRefGoogle Scholar
  141. 141.
    Franco M et al (2011) Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood 118(10):2906–2917PubMedPubMedCentralCrossRefGoogle Scholar
  142. 142.
    Betsholtz C (2004) Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev 15(4):215–228PubMedCrossRefGoogle Scholar
  143. 143.
    Guo P et al (2003) Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 162(4):1083–1093PubMedPubMedCentralCrossRefGoogle Scholar
  144. 144.
    Davis S et al (1996) Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87(7):1161–1169PubMedCrossRefGoogle Scholar
  145. 145.
    Maisonpierre PC et al (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277(5322):55–60PubMedCrossRefGoogle Scholar
  146. 146.
    Kiss EA, Saharinen P (2018) Anti-angiogenic targets: angiopoietin and angiopoietin-receptors. In: Marmé D (ed) Tumor angiogenesis: a key target for cancer therapy. Springer, Cham, pp 1–24Google Scholar
  147. 147.
    Reiss Y et al (2009) Switching of vascular phenotypes within a murine breast cancer model induced by angiopoietin-2. J Pathol 217(4):571–580PubMedCrossRefGoogle Scholar
  148. 148.
    Shim WS, Ho IA, Wong PE (2007) Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res 5(7):655–665PubMedCrossRefGoogle Scholar
  149. 149.
    Fiedler U et al (2006) Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 12(2):235–239PubMedCrossRefGoogle Scholar
  150. 150.
    Chae SS et al (2010) Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 16(14):3618–3627PubMedPubMedCentralCrossRefGoogle Scholar
  151. 151.
    Peterson TE et al (2016) Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci USA 113(16):4470–4475PubMedCrossRefGoogle Scholar
  152. 152.
    Kloepper J et al (2016) Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci USA 113(16):4476–4481PubMedCrossRefGoogle Scholar
  153. 153.
    Wu FT et al (2016) Efficacy of cotargeting angiopoietin-2 and the VEGF pathway in the adjuvant postsurgical setting for early breast, colorectal, and renal cancers. Cancer Res 76(23):6988–7000PubMedPubMedCentralCrossRefGoogle Scholar
  154. 154.
    Lisle JE et al (2013) Eph receptors and their ligands: promising molecular biomarkers and therapeutic targets in prostate cancer. Biochim Biophys Acta 1835(2):243–257PubMedGoogle Scholar
  155. 155.
    Kullander K, Klein R (2002) Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 3(7):475–486PubMedCrossRefGoogle Scholar
  156. 156.
    Holder N, Klein R (1999) Eph receptors and ephrins: effectors of morphogenesis. Development 126(10):2033–2044PubMedGoogle Scholar
  157. 157.
    Adams RH, Klein R (2000) Eph receptors and ephrin ligands. Essential mediators of vascular development. Trends Cardiovasc Med 10(5):183–188PubMedCrossRefGoogle Scholar
  158. 158.
    Surawska H, Ma PC, Salgia R (2004) The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 15(6):419–433PubMedCrossRefGoogle Scholar
  159. 159.
    Dodelet VC, Pasquale EB (2000) Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene 19(49):5614–5619PubMedCrossRefGoogle Scholar
  160. 160.
    Dong Y et al (2009) Downregulation of EphA1 in colorectal carcinomas correlates with invasion and metastasis. Mod Pathol 22(1):151–160PubMedCrossRefGoogle Scholar
  161. 161.
    Hafner C et al (2003) Loss of EphB6 expression in metastatic melanoma. Int J Oncol 23(6):1553–1559PubMedGoogle Scholar
  162. 162.
    Ogawa K et al (2000) The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19(52):6043–6052PubMedCrossRefGoogle Scholar
  163. 163.
    Dobrzanski P et al (2004) Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res 64(3):910–919PubMedCrossRefGoogle Scholar
  164. 164.
    Brantley DM et al (2002) Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21(46):7011–7026PubMedCrossRefGoogle Scholar
  165. 165.
    Cheng N et al (2003) Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. Neoplasia 5(5):445–456PubMedPubMedCentralCrossRefGoogle Scholar
  166. 166.
    Noren NK et al (2004) Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci USA 101(15):5583–5588PubMedCrossRefGoogle Scholar
  167. 167.
    Uhl C et al (2018) EphB4 mediates resistance to antiangiogenic therapy in experimental glioma. Angiogenesis 21(4):873–881PubMedPubMedCentralCrossRefGoogle Scholar
  168. 168.
    Krusche B et al (2016) EphrinB2 drives perivascular invasion and proliferation of glioblastoma stem-like cells. Elife 5:e14845PubMedPubMedCentralCrossRefGoogle Scholar
  169. 169.
    Wang Y et al (2010) Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 465(7297):483–486CrossRefGoogle Scholar
  170. 170.
    Sawamiphak S et al (2010) Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 465(7297):487–491PubMedCrossRefGoogle Scholar
  171. 171.
    Tatemoto K et al (1998) Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 251(2):471–476PubMedCrossRefGoogle Scholar
  172. 172.
    Devic E et al (1996) Expression of a new G protein-coupled receptor X-msr is associated with an endothelial lineage in Xenopus laevis. Mech Dev 59(2):129–140PubMedCrossRefGoogle Scholar
  173. 173.
    Cox CM et al (2006) Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol 296(1):177–189PubMedCrossRefGoogle Scholar
  174. 174.
    Kalin RE et al (2007) Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis. Dev Biol 305(2):599–614PubMedCrossRefGoogle Scholar
  175. 175.
    Wysocka MB, Pietraszek-Gremplewicz K, Nowak D (2018) The role of apelin in cardiovascular diseases, obesity and cancer. Front Physiol 9:557PubMedPubMedCentralCrossRefGoogle Scholar
  176. 176.
    Berta J et al (2010) Apelin expression in human non-small cell lung cancer: role in angiogenesis and prognosis. J Thorac Oncol 5(8):1120–1129PubMedCrossRefGoogle Scholar
  177. 177.
    Tolkach Y et al (2019) Apelin and apelin receptor expression in renal cell carcinoma. Br J Cancer 120(6):633–639PubMedCrossRefGoogle Scholar
  178. 178.
    Seaman S et al (2007) Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 11(6):539–554PubMedPubMedCentralCrossRefGoogle Scholar
  179. 179.
    Feng M et al (2016) Tumor apelin, not serum apelin, is associated with the clinical features and prognosis of gastric cancer. BMC Cancer 16(1):794PubMedPubMedCentralCrossRefGoogle Scholar
  180. 180.
    Lacquaniti A et al (2015) Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation. Clin Exp Med 15(1):97–105PubMedCrossRefGoogle Scholar
  181. 181.
    Heo K et al (2012) Hypoxia-induced up-regulation of apelin is associated with a poor prognosis in oral squamous cell carcinoma patients. Oral Oncol 48(6):500–506PubMedCrossRefGoogle Scholar
  182. 182.
    Hall C et al (2017) Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth. Cancer Lett 386:179–188PubMedCrossRefGoogle Scholar
  183. 183.
    Macaluso NJ et al (2011) Discovery of a competitive apelin receptor (APJ) antagonist. Chem Med Chem 6(6):1017–1023PubMedCrossRefGoogle Scholar
  184. 184.
    Lv D et al (2016) PAK1-cofilin phosphorylation mediates human lung adenocarcinoma cells migration induced by apelin-13. Clin Exp Pharmacol Physiol 43(5):569–579PubMedCrossRefGoogle Scholar
  185. 185.
    Berta J et al (2014) Apelin promotes lymphangiogenesis and lymph node metastasis. Oncotarget 5(12):4426–4437PubMedPubMedCentralCrossRefGoogle Scholar
  186. 186.
    Sorli SC et al (2007) Apelin is a potent activator of tumour neoangiogenesis. Oncogene 26(55):7692–7699PubMedCrossRefGoogle Scholar
  187. 187.
    Sorli SC et al (2006) Therapeutic potential of interfering with apelin signalling. Drug Discov Today 11(23–24):1100–1106PubMedCrossRefGoogle Scholar
  188. 188.
    Uribesalgo I et al (2019) Apelin inhibition prevents resistance and metastasis associated with anti-angiogenic therapy. EMBO Mol Med 11(8):e9266PubMedPubMedCentralGoogle Scholar
  189. 189.
    Mastrella G et al (2019) Targeting APLN/APLNR improves antiangiogenic efficiency and blunts proinvasive side effects of VEGFA/VEGFR2 blockade in glioblastoma. Cancer Res 79(9):2298–2313PubMedCrossRefGoogle Scholar
  190. 190.
    Harford-Wright E et al (2017) Pharmacological targeting of apelin impairs glioblastoma growth. Brain 140(11):2939–2954PubMedPubMedCentralCrossRefGoogle Scholar
  191. 191.
    Le Y et al (2004) Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell Mol Immunol 1(2):95–104PubMedGoogle Scholar
  192. 192.
    Heidemann J et al (2003) Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR192. J Biol Chem 278(10):8508–8515PubMedCrossRefGoogle Scholar
  193. 193.
    Keane MP et al (2004) Depletion of CXCR193 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 172(5):2853–2860PubMedCrossRefGoogle Scholar
  194. 194.
    Kitadai Y et al (2000) Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8. Clin Cancer Res 6(7):2735–2740PubMedGoogle Scholar
  195. 195.
    Ijichi H et al (2011) Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest 121(10):4106–4117PubMedPubMedCentralCrossRefGoogle Scholar
  196. 196.
    Yang G et al (2010) CXCR196 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res 16(15):3875–3886PubMedPubMedCentralCrossRefGoogle Scholar
  197. 197.
    Smith ML, Olson TS, Ley K (2004) CXCR197- and E-selectin-induced neutrophil arrest during inflammation in vivo. J Exp Med 200(7):935–939PubMedPubMedCentralCrossRefGoogle Scholar
  198. 198.
    Smith DR et al (1994) Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med 179(5):1409–1415PubMedCrossRefGoogle Scholar
  199. 199.
    Ha H, Debnath B, Neamati N (2017) Role of the CXCL8-CXCR199/2 axis in cancer and inflammatory diseases. Theranostics 7(6):1543–1588PubMedPubMedCentralCrossRefGoogle Scholar
  200. 200.
    Martin D, Galisteo R, Gutkind JS (2009) CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 284(10):6038–6042PubMedPubMedCentralCrossRefGoogle Scholar
  201. 201.
    Scapini P et al (2004) CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. J Immunol 172(8):5034–5040PubMedCrossRefGoogle Scholar
  202. 202.
    Zhao X et al (2009) ELR-CXC chemokine receptor antagonism targets inflammatory responses at multiple levels. J Immunol 182(5):3213–3222PubMedCrossRefGoogle Scholar
  203. 203.
    Li A et al (2005) Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis 8(1):63–71PubMedCrossRefGoogle Scholar
  204. 204.
    Kobayashi Y (2008) The role of chemokines in neutrophil biology. Front Biosci 13:2400–2407PubMedCrossRefGoogle Scholar
  205. 205.
    Sozzani S et al (2015) Chemokines as effector and target molecules in vascular biology. Cardiovasc Res 107(3):364–372PubMedCrossRefGoogle Scholar
  206. 206.
    Xu J et al (2017) Vascular CXCR206 expression promotes vessel sprouting and sensitivity to sorafenib treatment in hepatocellular carcinoma. Clin Cancer Res 23(15):4482–4492PubMedCrossRefGoogle Scholar
  207. 207.
    Ceradini DJ et al (2004) Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10(8):858–864PubMedCrossRefGoogle Scholar
  208. 208.
    Wolf MJ et al (2012) Endothelial CCR208 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell 22(1):91–105PubMedCrossRefGoogle Scholar
  209. 209.
    Chen X et al (2016) CCL2/CCR209 regulates the tumor microenvironment in HER-2/neu-driven mammary carcinomas in mice. PLoS One 11(11):e0165595PubMedPubMedCentralCrossRefGoogle Scholar
  210. 210.
    Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14(2):163–176PubMedPubMedCentralGoogle Scholar
  211. 211.
    Gupta MK, Qin RY (2003) Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol 9(6):1144–1155PubMedPubMedCentralCrossRefGoogle Scholar
  212. 212.
    Sainson RC et al (2008) TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. Blood 111(10):4997–5007PubMedPubMedCentralCrossRefGoogle Scholar
  213. 213.
    Muramatsu T (2002) Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem 132(3):359–371PubMedCrossRefGoogle Scholar
  214. 214.
    Lu KV et al (2005) Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J Biol Chem 280(29):26953–26964PubMedCrossRefGoogle Scholar
  215. 215.
    Chen H et al (2009) Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis. Blood 113(9):1992–2002PubMedPubMedCentralCrossRefGoogle Scholar
  216. 216.
    Zhang L et al (2015) Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas. Sci Signal 8(406):ra125PubMedCrossRefGoogle Scholar
  217. 217.
    Cai Y et al (2005) Identification of a new RTN3 transcript, RTN3-A1, and its distribution in adult mouse brain. Brain Res Mol Brain Res 138(2):236–243PubMedCrossRefGoogle Scholar
  218. 218.
    Yang J et al (2000) Assignment of the human reticulon 4 gene (RTN4) to chromosome 2p14– > 2p13 by radiation hybrid mapping. Cytogenet Cell Genet 88(1–2):101–102PubMedCrossRefGoogle Scholar
  219. 219.
    Acevedo L et al (2004) A new role for Nogo as a regulator of vascular remodeling. Nat Med 10(4):382–388PubMedCrossRefGoogle Scholar
  220. 220.
    Yu J et al (2009) Reticulon 4B (Nogo-B) is necessary for macrophage infiltration and tissue repair. Proc Natl Acad Sci USA 106(41):17511–17516PubMedCrossRefGoogle Scholar
  221. 221.
    Zhu B et al (2017) Knockout of the Nogo-B gene attenuates tumor growth and metastasis in hepatocellular carcinoma. Neoplasia 19(7):583–593PubMedPubMedCentralCrossRefGoogle Scholar
  222. 222.
    Cai H et al (2018) Nogo-B promotes tumor angiogenesis and provides a potential therapeutic target in hepatocellular carcinoma. Mol Oncol 12(12):2042–2054PubMedPubMedCentralCrossRefGoogle Scholar
  223. 223.
    Lv X et al (2017) The role of hypoxia-inducible factors in tumor angiogenesis and cell metabolism. Genes Dis 4(1):19–24PubMedCrossRefGoogle Scholar
  224. 224.
    Liao D, Johnson RS (2007) Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 26(2):281–290PubMedCrossRefGoogle Scholar
  225. 225.
    Miller F et al (2005) Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL. Hypoxia-inducible transcription factor-1alpha complex. J Biol Chem 280(9):7985–7996PubMedCrossRefGoogle Scholar
  226. 226.
    Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21(3):309–322CrossRefGoogle Scholar
  227. 227.
    de Visser KE, Coussens LM (2006) The inflammatory tumor microenvironment and its impact on cancer development. Contrib Microbiol 13:118–137PubMedCrossRefGoogle Scholar
  228. 228.
    Benelli R et al (2006) Cytokines and chemokines as regulators of angiogenesis in health and disease. Curr Pharm Des 12(24):3101–3115PubMedCrossRefGoogle Scholar
  229. 229.
    Albini A et al (2018) Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: implications for immunotherapy. Front Immunol 9:527PubMedPubMedCentralCrossRefGoogle Scholar
  230. 230.
    Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7(3):211–217PubMedCrossRefGoogle Scholar
  231. 231.
    Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22(2):231–237PubMedCrossRefGoogle Scholar
  232. 232.
    Biswas SK et al (2006) A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107(5):2112–2122PubMedCrossRefGoogle Scholar
  233. 233.
    Lin EY et al (2006) Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66(23):11238–11246PubMedCrossRefGoogle Scholar
  234. 234.
    Zhang W et al (2010) Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 16(13):3420–3430PubMedCrossRefGoogle Scholar
  235. 235.
    Spiric Z, Eri Z, Eric M (2015) Significance of vascular endothelial growth factor (VEGF)-C and VEGF-D in the progression of cutaneous melanoma. Int J Surg Pathol 23(8):629–637PubMedCrossRefGoogle Scholar
  236. 236.
    Zhou H et al (2012) Semaphorin 4D cooperates with VEGF to promote angiogenesis and tumor progression. Angiogenesis 15(3):391–407PubMedPubMedCentralCrossRefGoogle Scholar
  237. 237.
    Cejudo-Martin P et al (2002) Hypoxia is an inducer of vasodilator agents in peritoneal macrophages of cirrhotic patients. Hepatology 36(5):1172–1179PubMedCrossRefGoogle Scholar
  238. 238.
    Klimp AH et al (2001) Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res 61(19):7305–7309PubMedGoogle Scholar
  239. 239.
    Giraudo E, Inoue M, Hanahan D (2004) An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114(5):623–633PubMedPubMedCentralCrossRefGoogle Scholar
  240. 240.
    Gocheva V et al (2010) IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 24(3):241–255PubMedPubMedCentralCrossRefGoogle Scholar
  241. 241.
    Zhang J et al (2011) Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model. Neoplasia 13(1):23–30PubMedPubMedCentralCrossRefGoogle Scholar
  242. 242.
    Shen Z et al (2012) Vasohibin-1 and vasohibin-2 expression in gastric cancer cells and TAMs. Med Oncol 29(4):2718–2726PubMedCrossRefGoogle Scholar
  243. 243.
    Welford AF et al (2011) TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Invest 121(5):1969–1973PubMedPubMedCentralCrossRefGoogle Scholar
  244. 244.
    Bronte V et al (2016) Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 7:12150PubMedPubMedCentralCrossRefGoogle Scholar
  245. 245.
    Parker KH, Beury DW, Ostrand-Rosenberg S (2015) Myeloid-derived suppressor cells: critical cells driving immune suppression in the tumor microenvironment. Adv Cancer Res 128:95–139PubMedPubMedCentralCrossRefGoogle Scholar
  246. 246.
    Coffelt SB, Wellenstein MD, de Visser KE (2016) Neutrophils in cancer: neutral no more. Nat Rev Cancer 16(7):431–446PubMedCrossRefGoogle Scholar
  247. 247.
    Kumar V et al (2016) The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 37(3):208–220PubMedPubMedCentralCrossRefGoogle Scholar
  248. 248.
    Jacob A, Prekeris R (2015) The regulation of MMP targeting to invadopodia during cancer metastasis. Front Cell Dev Biol 3:4PubMedPubMedCentralCrossRefGoogle Scholar
  249. 249.
    Horikawa N et al (2017) Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells. Clin Cancer Res 23(2):587–599PubMedCrossRefGoogle Scholar
  250. 250.
    Karakhanova S et al (2015) Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells. Oncoimmunology 4(4):e998519PubMedPubMedCentralCrossRefGoogle Scholar
  251. 251.
    Chun E et al (2015) CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function. Cell Rep 12(2):244–257PubMedPubMedCentralCrossRefGoogle Scholar
  252. 252.
    Obermajer N et al (2011) PGE(2)-induced CXCL12 production and CXCR252 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 71(24):7463–7470PubMedPubMedCentralCrossRefGoogle Scholar
  253. 253.
    Shojaei F et al (2007) Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450(7171):825–831PubMedCrossRefGoogle Scholar
  254. 254.
    Piao Y et al (2012) Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol 14(11):1379–1392PubMedPubMedCentralCrossRefGoogle Scholar
  255. 255.
    Hao Z, Sadek I (2016) Sunitinib: the antiangiogenic effects and beyond. Onco Targets Ther 9:5495–5505PubMedPubMedCentralCrossRefGoogle Scholar
  256. 256.
    van Hooren L et al (2016) Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment. Oncotarget 7(31):50277–50289PubMedPubMedCentralGoogle Scholar
  257. 257.
    Tecchio C et al (2013) On the cytokines produced by human neutrophils in tumors. Semin Cancer Biol 23(3):159–170PubMedCrossRefGoogle Scholar
  258. 258.
    Mueller MD et al (2000) Neutrophils infiltrating the endometrium express vascular endothelial growth factor: potential role in endometrial angiogenesis. Fertil Steril 74(1):107–112PubMedCrossRefGoogle Scholar
  259. 259.
    Heryanto B, Girling JE, Rogers PA (2004) Intravascular neutrophils partially mediate the endometrial endothelial cell proliferative response to oestrogen in ovariectomised mice. Reproduction 127(5):613–620PubMedCrossRefGoogle Scholar
  260. 260.
    Shaw JP et al (2003) Polymorphonuclear neutrophils promote rFGF-2-induced angiogenesis in vivo. J Surg Res 109(1):37–42PubMedCrossRefGoogle Scholar
  261. 261.
    Benelli R et al (2002) Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB J 16(2):267–269PubMedCrossRefGoogle Scholar
  262. 262.
    Nozawa H, Chiu C, Hanahan D (2006) Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 103(33):12493–12498PubMedCrossRefGoogle Scholar
  263. 263.
    Shaul ME, Fridlender ZG (2017) Neutrophils as active regulators of the immune system in the tumor microenvironment. J Leukoc Biol 102(2):343–349PubMedCrossRefGoogle Scholar
  264. 264.
    Fridlender ZG et al (2009) Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 16(3):183–194PubMedPubMedCentralCrossRefGoogle Scholar
  265. 265.
    Grenier A et al (2002) Presence of a mobilizable intracellular pool of hepatocyte growth factor in human polymorphonuclear neutrophils. Blood 99(8):2997–3004PubMedCrossRefGoogle Scholar
  266. 266.
    Dubravec DB et al (1990) Circulating human peripheral blood granulocytes synthesize and secrete tumor necrosis factor alpha. Proc Natl Acad Sci USA 87(17):6758–6761PubMedCrossRefGoogle Scholar
  267. 267.
    Kujawski M et al (2008) Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118(10):3367–3377PubMedPubMedCentralCrossRefGoogle Scholar
  268. 268.
    Ardi VC et al (2007) Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 104(51):20262–20267PubMedCrossRefGoogle Scholar
  269. 269.
    Hanna J et al (2006) Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 12(9):1065–1074PubMedCrossRefGoogle Scholar
  270. 270.
    Blois SM, Klapp BF, Barrientos G (2011) Decidualization and angiogenesis in early pregnancy: unravelling the functions of DC and NK cells. J Reprod Immunol 88(2):86–92PubMedCrossRefGoogle Scholar
  271. 271.
    Keskin DB et al (2007) TGFbeta promotes conversion of CD16 + peripheral blood NK cells into CD16- NK cells with similarities to decidual NK cells. Proc Natl Acad Sci USA 104(9):3378–3383PubMedCrossRefGoogle Scholar
  272. 272.
    Bruno A et al (2013) The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. Neoplasia 15(2):133–142PubMedPubMedCentralCrossRefGoogle Scholar
  273. 273.
    Gao Y et al (2017) Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat Immunol 18(9):1004–1015PubMedCrossRefGoogle Scholar
  274. 274.
    Yang C et al (2013) B cells promote tumor progression via STAT3 regulated-angiogenesis. PLoS One 8(5):e64159PubMedPubMedCentralCrossRefGoogle Scholar
  275. 275.
    Andreu P et al (2010) FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17(2):121–134PubMedPubMedCentralCrossRefGoogle Scholar
  276. 276.
    Blotnick S et al (1994) T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4 + and CD8 + T cells. Proc Natl Acad Sci USA 91(8):2890–2894PubMedCrossRefGoogle Scholar
  277. 277.
    Fathallah-Shaykh HM et al (2000) Gene transfer of IFN-gamma into established brain tumors represses growth by antiangiogenesis. J Immunol 164(1):217–222PubMedCrossRefGoogle Scholar
  278. 278.
    Friesel R, Komoriya A, Maciag T (1987) Inhibition of endothelial cell proliferation by gamma-interferon. J Cell Biol 104(3):689–696PubMedCrossRefGoogle Scholar
  279. 279.
    Madri JA, Pratt BM, Tucker AM (1988) Phenotypic modulation of endothelial cells by transforming growth factor-beta depends upon the composition and organization of the extracellular matrix. J Cell Biol 106(4):1375–1384PubMedCrossRefGoogle Scholar
  280. 280.
    Belardelli F et al (1983) Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. III. Inhibition of growth and necrosis of tumors implanted subcutaneously. Int J Cancer 31(5):649–653PubMedCrossRefGoogle Scholar
  281. 281.
    Sato N et al (1990) Actions of TNF and IFN-gamma on angiogenesis in vitro. J Invest Dermatol 95(6 Suppl):85S–89SPubMedCrossRefGoogle Scholar
  282. 282.
    Maheshwari RK et al (1991) Differential effects of interferon gamma and alpha on in vitro model of angiogenesis. J Cell Physiol 146(1):164–169PubMedCrossRefGoogle Scholar
  283. 283.
    Fridman WH et al (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298–306PubMedCrossRefGoogle Scholar
  284. 284.
    Strieter RM et al (2005) CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 16(6):593–609PubMedCrossRefGoogle Scholar
  285. 285.
    Burdick MD et al (2005) CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med 171(3):261–268PubMedCrossRefGoogle Scholar
  286. 286.
    Lasagni L et al (2003) An alternatively spliced variant of CXCR286 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med 197(11):1537–1549PubMedPubMedCentralCrossRefGoogle Scholar
  287. 287.
    Vasudev NS, Reynolds AR (2014) Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 17(3):471–494PubMedPubMedCentralCrossRefGoogle Scholar
  288. 288.
    de Gramont A et al (2012) Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 13(12):1225–1233PubMedCrossRefGoogle Scholar
  289. 289.
    Yang Y et al (2016) Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism. Nat Commun 7:12680PubMedPubMedCentralCrossRefGoogle Scholar
  290. 290.
    Haemmerle M et al (2016) FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest 126(5):1885–1896PubMedPubMedCentralCrossRefGoogle Scholar
  291. 291.
    Paez-Ribes M et al (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3):220–231PubMedPubMedCentralCrossRefGoogle Scholar
  292. 292.
    Ebos JM et al (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3):232–239PubMedPubMedCentralCrossRefGoogle Scholar
  293. 293.
    Wang N, Jain RK, Batchelor TT (2017) New directions in anti-angiogenic therapy for glioblastoma. Neurotherapeutics 14(2):321–332PubMedPubMedCentralCrossRefGoogle Scholar
  294. 294.
    Lucio-Eterovic AK, Piao Y, de Groot JF (2009) Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 15(14):4589–4599PubMedCrossRefGoogle Scholar
  295. 295.
    Lu KV et al (2012) VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22(1):21–35PubMedPubMedCentralCrossRefGoogle Scholar
  296. 296.
    Jahangiri A et al (2017) Cross-activating c-Met/beta1 integrin complex drives metastasis and invasive resistance in cancer. Proc Natl Acad Sci USA 114(41):E8685–E8694PubMedCrossRefGoogle Scholar
  297. 297.
    Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8(8):592–603PubMedPubMedCentralCrossRefGoogle Scholar
  298. 298.
    Zarrin B et al (2017) Acquired tumor resistance to antiangiogenic therapy: mechanisms at a glance. J Res Med Sci 22:117PubMedPubMedCentralCrossRefGoogle Scholar
  299. 299.
    Liu ZJ, Semenza GL, Zhang HF (2015) Hypoxia-inducible factor 1 and breast cancer metastasis. J Zhejiang Univ Sci B 16(1):32–43PubMedPubMedCentralCrossRefGoogle Scholar
  300. 300.
    Kuczynski EA et al (2016) Co-option of liver vessels and not sprouting angiogenesis drives acquired sorafenib resistance in hepatocellular carcinoma. J Natl Cancer Inst 108(8). CrossRefPubMedPubMedCentralGoogle Scholar
  301. 301.
    Serova M et al (2016) Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib. Oncotarget 7(25):38467–38486PubMedPubMedCentralCrossRefGoogle Scholar
  302. 302.
    Shaaban S et al (2016) Targeting bone marrow to potentiate the anti-tumor effect of tyrosine kinase inhibitor in preclinical rat model of human glioblastoma. Int J Cancer Res 12(2):69–81PubMedPubMedCentralCrossRefGoogle Scholar
  303. 303.
    Moccia F et al (2015) Endothelial progenitor cells support tumour growth and metastatisation: implications for the resistance to anti-angiogenic therapy. Tumour Biol 36(9):6603–6614PubMedCrossRefGoogle Scholar
  304. 304.
    Rivera LB et al (2015) Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. Cell Rep 11(4):577–591PubMedPubMedCentralCrossRefGoogle Scholar
  305. 305.
    Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96(12):1788–1795PubMedPubMedCentralCrossRefGoogle Scholar
  306. 306.
    Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10(6):417–427PubMedCrossRefGoogle Scholar
  307. 307.
    Goel S et al (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91(3):1071–1121PubMedPubMedCentralCrossRefGoogle Scholar
  308. 308.
    Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7(9):987–989PubMedCrossRefGoogle Scholar
  309. 309.
    Jayson GC, Hicklin DJ, Ellis LM (2012) Antiangiogenic therapy—evolving view based on clinical trial results. Nat Rev Clin Oncol 9(5):297–303PubMedCrossRefGoogle Scholar
  310. 310.
    Mazzone M et al (2009) Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136(5):839–851PubMedPubMedCentralCrossRefGoogle Scholar
  311. 311.
    Sorensen AG et al (2009) A “vascular normalization index” as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69(13):5296–5300PubMedPubMedCentralCrossRefGoogle Scholar
  312. 312.
    Batchelor TT et al (2013) Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA 110(47):19059–19064PubMedCrossRefGoogle Scholar
  313. 313.
    Sorensen AG et al (2012) Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 72(2):402–407PubMedCrossRefGoogle Scholar
  314. 314.
    Shrimali RK et al (2010) Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 70(15):6171–6180PubMedPubMedCentralCrossRefGoogle Scholar
  315. 315.
    Yang J, Yan J, Liu B (2018) Targeting VEGF/VEGFR to modulate antitumor immunity. Front Immunol 9:978PubMedPubMedCentralCrossRefGoogle Scholar
  316. 316.
    Xin H et al (2009) Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 69(6):2506–2513PubMedPubMedCentralCrossRefGoogle Scholar
  317. 317.
    Adotevi O et al (2010) A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 33(9):991–998PubMedCrossRefGoogle Scholar
  318. 318.
    Martino EC et al (2016) Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients. Cell Death Discov 2:16025PubMedPubMedCentralCrossRefGoogle Scholar
  319. 319.
    Olsson AK (2014) Therapeutic vaccination targeting the tumour vasculature. Biochem Soc Trans 42(6):1653–1657PubMedCrossRefGoogle Scholar
  320. 320.
    Huijbers EJ et al (2010) Vaccination against the extra domain-B of fibronectin as a novel tumor therapy. FASEB J 24(11):4535–4544PubMedCrossRefGoogle Scholar
  321. 321.
    Femel J et al (2014) Therapeutic vaccination against fibronectin ED-A attenuates progression of metastatic breast cancer. Oncotarget 5(23):12418–12427PubMedPubMedCentralCrossRefGoogle Scholar
  322. 322.
    Chaudhary A et al (2012) TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. Cancer Cell 21(2):212–226PubMedPubMedCentralCrossRefGoogle Scholar
  323. 323.
    Szot C et al (2018) Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release. J Clin Invest 128(7):2927–2943PubMedPubMedCentralCrossRefGoogle Scholar
  324. 324.
    Byrd TT et al (2018) TEM8/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer. Cancer Res 78(2):489–500PubMedCrossRefGoogle Scholar
  325. 325.
    Hamzah J et al (2008) Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. J Clin Invest 118(5):1691–1699PubMedPubMedCentralCrossRefGoogle Scholar
  326. 326.
    Johansson A et al (2012) Tumor-targeted TNFalpha stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci USA 109(20):7841–7846PubMedCrossRefGoogle Scholar
  327. 327.
    Khan KA, Kerbel RS (2018) Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol 15(5):310–324PubMedCrossRefGoogle Scholar
  328. 328.
    Georganaki M, van Hooren L, Dimberg A (2018) Vascular targeting to increase the efficiency of immune checkpoint blockade in cancer. Front Immunol 9:3081PubMedPubMedCentralCrossRefGoogle Scholar
  329. 329.
    Hayasaka H et al (2010) Neogenesis and development of the high endothelial venules that mediate lymphocyte trafficking. Cancer Sci 101(11):2302–2308PubMedCrossRefGoogle Scholar
  330. 330.
    Hindley JP et al (2012) T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion. Cancer Res 72(21):5473–5482PubMedPubMedCentralCrossRefGoogle Scholar
  331. 331.
    Colbeck EJ et al (2017) Treg depletion licenses T cell-driven HEV neogenesis and promotes tumor destruction. Cancer Immunol Res 5(11):1005–1015PubMedPubMedCentralCrossRefGoogle Scholar
  332. 332.
    Allen E et al (2017) Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med 9(385):eaak9679PubMedPubMedCentralCrossRefGoogle Scholar
  333. 333.
    He B et al (2018) Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules. J Pathol 245(2):209–221PubMedPubMedCentralCrossRefGoogle Scholar
  334. 334.
    Patel MM, Patel BM (2017) Crossing the blood-brain barrier: recent advances in drug delivery to the brain. CNS Drugs 31(2):109–133PubMedPubMedCentralCrossRefGoogle Scholar
  335. 335.
    Sandler A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550PubMedPubMedCentralCrossRefGoogle Scholar
  336. 336.
    Tewari KS et al (2017) Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 390(10103):1654–1663PubMedPubMedCentralCrossRefGoogle Scholar
  337. 337.
    Perren TJ et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26):2484–2496PubMedCrossRefGoogle Scholar
  338. 338.
    Escudier B et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103–2111PubMedCrossRefGoogle Scholar
  339. 339.
    Wick W et al (2017) Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377(20):1954–1963PubMedPubMedCentralCrossRefGoogle Scholar
  340. 340.
    Fuchs CS et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383(9911):31–39PubMedCrossRefGoogle Scholar
  341. 341.
    Tabernero J et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16(5):499–508PubMedCrossRefGoogle Scholar
  342. 342.
    Zhu AX et al (2019) Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20(2):282–296PubMedCrossRefGoogle Scholar
  343. 343.
    Garon EB et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384(9944):665–673CrossRefGoogle Scholar
  344. 344.
    Bonner JA et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578PubMedCrossRefGoogle Scholar
  345. 345.
    Heinemann V et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15(10):1065–1075PubMedCrossRefGoogle Scholar
  346. 346.
    Price TJ et al (2014) Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 15(6):569–579PubMedCrossRefGoogle Scholar
  347. 347.
    Thatcher N et al (2015) Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 16(7):763–774PubMedCrossRefGoogle Scholar
  348. 348.
    Gianni L et al (2014) Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol 15(6):640–647PubMedCrossRefGoogle Scholar
  349. 349.
    Bang YJ et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697PubMedCrossRefGoogle Scholar
  350. 350.
    Hurvitz SA et al (2018) Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 19(1):115–126PubMedCrossRefGoogle Scholar
  351. 351.
    Llovet JM et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390PubMedCrossRefGoogle Scholar
  352. 352.
    Escudier B et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134PubMedCrossRefGoogle Scholar
  353. 353.
    Brose MS et al (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384(9940):319–328PubMedPubMedCentralCrossRefGoogle Scholar
  354. 354.
    Demetri GD et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329–1338PubMedCrossRefGoogle Scholar
  355. 355.
    Raymond E et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501–513PubMedCrossRefGoogle Scholar
  356. 356.
    Motzer RJ et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584–3590PubMedPubMedCentralCrossRefGoogle Scholar
  357. 357.
    Dematteo RP et al (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373(9669):1097–1104PubMedPubMedCentralCrossRefGoogle Scholar
  358. 358.
    Druker BJ et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408–2417PubMedCrossRefGoogle Scholar
  359. 359.
    Fielding AK et al (2014) UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 123(6):843–850PubMedPubMedCentralCrossRefGoogle Scholar
  360. 360.
    Motzer RJ et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722–731PubMedCrossRefGoogle Scholar
  361. 361.
    van der Graaf WT et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379(9829):1879–1886PubMedCrossRefGoogle Scholar
  362. 362.
    Kim ES et al (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372(9652):1809–1818PubMedCrossRefGoogle Scholar
  363. 363.
    Lee SM et al (2012) First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 13(11):1161–1170PubMedPubMedCentralCrossRefGoogle Scholar
  364. 364.
    Moore MJ et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15):1960–1966PubMedCrossRefGoogle Scholar
  365. 365.
    Wells SA Jr et al (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30(2):134–141PubMedCrossRefGoogle Scholar
  366. 366.
    Li J et al (2015) Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 16(6):619–629PubMedCrossRefGoogle Scholar
  367. 367.
    Demetri GD et al (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):295–302PubMedCrossRefGoogle Scholar
  368. 368.
    Bruix J et al (2017) Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389(10064):56–66PubMedCrossRefGoogle Scholar
  369. 369.
    Martin M et al (2017) Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18(12):1688–1700CrossRefGoogle Scholar
  370. 370.
    Baselga J et al (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379(9816):633–640PubMedPubMedCentralCrossRefGoogle Scholar
  371. 371.
    Sequist LV et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31(27):3327–3334CrossRefGoogle Scholar
  372. 372.
    Rini BI et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807):1931–1939PubMedCrossRefGoogle Scholar
  373. 373.
    Abou-Alfa GK et al (2018) Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 379(1):54–63PubMedCrossRefGoogle Scholar
  374. 374.
    Elisei R et al (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31(29):3639–3646PubMedPubMedCentralCrossRefGoogle Scholar
  375. 375.
    Powles T et al (2018) Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer 119(6):663–669PubMedPubMedCentralCrossRefGoogle Scholar
  376. 376.
    Kudo M et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126):1163–1173PubMedCrossRefGoogle Scholar
  377. 377.
    Schlumberger M et al (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372(7):621–630PubMedCrossRefGoogle Scholar
  378. 378.
    Tabernero J et al (2014) Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 50(2):320–331PubMedCrossRefGoogle Scholar
  379. 379.
    Rajkumar SV et al (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20(21):4319–4323PubMedCrossRefGoogle Scholar
  380. 380.
    Rajkumar SV et al (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 11(1):29–37PubMedCrossRefGoogle Scholar
  381. 381.
    Motzer RJ et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456PubMedCrossRefGoogle Scholar
  382. 382.
    Baselga J et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520–529CrossRefGoogle Scholar
  383. 383.
    Yao JC et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514–523PubMedPubMedCentralCrossRefGoogle Scholar
  384. 384.
    Pavel ME et al (2017) Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18(10):1411–1422PubMedCrossRefGoogle Scholar
  385. 385.
    Franz DN et al (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381(9861):125–132PubMedCrossRefGoogle Scholar

Copyright information

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.The Rudbeck Laboratory, Department of Immunology, Genetics and PathologyUppsala UniversityUppsalaSweden

Personalised recommendations